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1. Introduction 
 
1.1 ALLERGIC DISEASES 
 
The immune system is a very complex system that protects the body from harmful elements, 
whether from self or non-self origin. When this system is compromised, infections, cancer, 
autoimmune diseases or allergic diseases can develop. 
Allergic diseases comprise atopic dermatitis (eczema), allergic asthma, allergic rhinitis and 
conjunctivitis (rhinoconjutivitis or hay fever) and systemic anaphylaxis. These affect both 
adults and children (Asher, 2004).  
Allergic diseases are characterized by an aberrant immune response to generally harmless 
antigens. The common allergens in westernized countries (antigens that can cause allergic 
reactions) include house dust mite, grass pollen, Alternaria alternata, Cladosporium 
herbarum, cat and dog dander, cow’s milk, peanut, hen’s egg, soya, cod and wheat (Arshad et 
al. 2001). 
Currently, allergic diseases have reached epidemic proportions worldwide, it is estimated that 
30-40 % of the world’s population is affected (Pawankar, 2011). Therefore, it is of extreme 
importance to disentangle the origins and mechanisms of allergic diseases for the 
development of future therapies. 
 
1.1.1 The socio-economic relevance of allergic diseases 
 
The dramatic increase of allergic diseases, about 3 time fold in the last half century (Asher, 
2004) lead to a significant financial burden on thehealthcare systems (O’Connell, 2004). 
Predictions estimate that in approximately 10 years there could be 400 million people 
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suffering from asthma (Pawankar, 2011). The financil osts also impact the families as in 
medical services and prescription drugs (Suh, 2007). 
Likewise there are social and physical costs associated with lowered life quality of the 
patients. This ranges from missed work and school days, urgent visits to the doctor, inability 
to practice sports, constant vigilance in food uptake nd increased stress levels (O'Connell, 
2004; von Mutius, 2000; Klinnert, 2008). 
Atopic dermatitis leads for instance to constant itchiness, which is worsened by night time 
with a direct impact on the sleep patterns and is associated with decreased life quality (Monti 
et al. 1989). 
Several studies have shown that there can be severe psychological effects on patients with 
allergic diseases and their families, which require guidance from the healthcare providers 
(Klinnert et al. 2008). Therefore, patients and closer relatives ar not only socio-economically 
affected by allergic diseases, but also physically nd psycologically, becoming a heavy 
burden on their daily lives. 
 
1.1.2 Clinical manifestations of allergic diseases 
  
1.1.2.1 Atopic dermatitis (eczema) 
Atopic dermatitis (AD) is characterized by a chronic and relapsing skin inflammation with 
pruritus (itching), resulting in dry skin with an impaired function of the healthy epidermal-
barrier. The symptoms include eczematous papules and plaques (Bieber, 2008; Simpson, 
2010). The location of the lesions varies and can affect several parts of the body, such as the 
cheeks, scalp, neck and the flexures (elbows, the back of the knees) (Bieber, 2008). 
The prevalence of atopic dermatitis is two times higher in children compared to adults 
(Williams et al. 2006). AD usually has a very early-onset, with 60 % starting before the age of 
1 year, however, the majority of the children outgrow atopic dermatitis before reaching 
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adolescence (Novak et al. 2003). Histologic analyses show that the plaques ar  characterized 
by epidermal oedema and high levels of immune cell infi trates (such as eosinophils, 
lymphocytes and dendritic cells) (Bieber et al. 2008). 
 
1.1.2.2 Allergic asthma 
Asthma is a complex airway disorder that is characterized by four main features: airway 
obstruction, hyperresponsiveness, spontaneous (or treatment-associated) reversibility and 
inflammation (Lemanske t al. 2010). The manifestation of asthma can be mild, moderate up 
to extreme cases, life-threatening due to asphyxia (Corry, 2001). The episodes of exacerbation 
are triggered by exposure to allergens in sensitized subjects (Lemanske et al. 2010). This is 
one of the hallmarks that differentiates allergic from non-allergic asthma, which is generally 
triggered by physical activity, stress, cold air and viral infections (Romanet-Manent e al. 
2002). For the majority of the patients, the onset tarts during early childhood and is 
accompanied by a pattern of decreased lung function (Lemanske et al. 2010).  
Although the onset is usually before the age of 4 years, there are several limitations in 
assessing the disease. For instance, wheezing can be ssessed with or without a stethoscope 
while airway obstruction can be indirectly measured by detailed lung function testing (which 
is reliable to perform usually from the age of 5 years on), however there are scarce ways of 
imaging the airways and lungs (von Mutius, 2009). Furthermore, one of the main features of 
airway obstruction in asthmatics is its transiency. Although peak flow variability provides 
valuable information, there are no means to study the airway size and tone, particularly in 
small children (von Mutius, 2009). Thus this represent  a holdup in the study of asthma at 
very young ages (Frey et al. 2009; Depner et al. 2013, submitted). 
Studies have shown the presence of cellular infiltrates in the lung periphery of inflammatory 
cells in cases of fatal asthma (Saetta  l. 1991; Synek et al. 1996). Also the density of these 
cell infiltrates has been linked to peripheral airwy obstruction (Hayley et al.1998).  
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1.1.2.3 Allergic rhinitis 
Allergic rhinitis affects an estimate of 1.4 billion people worldwide and following the same 
pattern of the two other aforementioned allergic diseases, it continues to rise. The symptoms 
of this disorder comprise itching of the nasal area, inner ear, soft palate, nasal congestion and 
rhinorrhea in response to airborne allergens. The most common causal allergens are pollen, 
dust mites and dog or cat dander (Uzzaman et al. 2012; Skoner, 2001). 
Furthermore, allergic rhinitis is often associated with other conditions such as sinusitis, otitis 
media, nasal polyps and asthma. 
The features of allergic rhinitis result from infiltration of inflammatory cells in the nasal 
mucosa and mediators modulated by specific Immunoglobulin E (IgE) production in 
sensitized individuals (Settipane et al. 2013). 
  
 
1.1.2.4 Anaphylaxis  
This form of allergic disease is a severe systemic reaction with an acute-onset. The main 
triggers are food, drugs or insect stings. Although the symptoms can be mild in some cases, it 
can be life-threatening in a matter of minutes (Simons, 2008).  
In the literature anaphylaxis is also referred to as a syndrome and not as a “disease” with 
varied clinical manifestations such as: hypotension, cardiac arrhythmias, laryngeal oedema, 
bronchospasm, diffused erythema and pruritus (Kemp t al. 2002). 
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1.2 ROLE OF T CELL LYMPHOCYTES IN ALLERGIC DISEASES  
 
There are different immune cells, such as dendritic cells, mast cells, eosinophils, lymphocytes 
and other subsets involved in allergies. T lymphocytes (Th1, Th2 and regulatory T cells) are 
the focus in the present work.  
 
1.2.1 Th1 and Th2 cells  
 
Lymphocytes constitute of different effector T cells. These cells secrete different pattern of 
cytokines, preferentially express different markers and characteristic transcription factors, 
respond differently to stimulation and induce different immune responses.  
Interferon-gamma (IFN-γ) is the Th1 hallmark cytokine; Th1 cells also produce interleukin 
(IL)-2 and tumor necrosis factor-beta (TNF-β) which are not produced by Th2 cells. Th1 
cytokines are important for elimination of intracellular pathogens (Berger, 2000; Rengarajan 
et al. 2000) but also in the developmental phase of allergies. Th2 but not Th1 cells, produce 
the characteristic interleukins IL-4, IL-5, IL-13 and IL-10, which are important for immunity 
against helminthic infections. Both Th1 and Th2 secrete IL-3, IL-6, granulocyte macrophage 
colony-stimulating factor (GM-CSF) and tumor necrosis factor-alpha, TNF-α (Del Prete, 
1992). 
Th1 and Th2 can counter-balance each other. Dysregulation of these cell subtypes is known as 
the Th1/Th2 paradigm (Berger, 2000; Rengarajan et al. 2000).  
Apart from the classical Th1 and Th2 cells, other effector cell types have been identified: 
Th17 and Th9 cells, which have characteristic cytokine profiles and transcription factors.  
Figure 1 shows the main transcription factors and cytokines secreted by different T cell 
population. 
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Th1 and Th2 cells are as well regulated differently and have characteristic transcriptional 
regulation. T-box expressed in T cells (T-bet, encoded by the TBX21 gene) is an important 
transcription factor (TF) of the Th1 lineage. Additionally, it was shown that T-bet interacts 
closely with another transcription factor, H2.0-like homeo box 1, HLX1 (Mullen et al. 2002). 
Together they induce Th1 cell differentiation and suppress the Th2 cell lineage (Mullen t al. 
2002). In contrast, Th2 cells are strongly regulated by two characteristic transcription factors:  
signal transducer and activator of transcription 6 (STAT6), which induces the transcription 
factor GATA-binding protein 3 (GATA3) (Zhu et al. 2010). 
 
1.2.2 Regulatory T cells 
 
Although other cell types have recently been shown to have suppressive capacity, regulatory 
T cells (Treg cells) have the main specialized rolein suppressing cellular responses of other 
immune cells. This is crucial for the maintenance of peripheral homeostasis and for self and 
foreign tolerance. A large body of mouse and human studies has shown that impairment of 
these cells is associated with autoimmunity and allergic diseases (Sakaguchi, 2008). 
Different Treg subsets have been described based on their phenotype and regulatory 
mechanisms. Naturally occurring Treg cells (nTreg clls) originate from the thymus and are 
characterized by the expression of CD4, high levels of CD25 (IL-2 receptor) and expression 
of Forkhead box protein 3–positive (FOXP3) (Vignali et al. 2008). FOXP3 is known as the 
master gene regulating the natural Treg cells, encodi g for the TF FOXP3.  
Furthermore there are induced or adaptive Treg cells (iTreg cells), which acquire suppressive 
capacity under specific conditions in the periphery. Those include Tr1 cells that secrete the 
anti-inflammatory cytokine IL-10 and Tr3 cells that produce transforming growth factor beta 
(TGF-β) (Sakaguchi et al. 2010). 
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Different mechanisms of suppression have been proposed. Besides secretion of the inhibitory 
cytokines IL-10 and TGF-β, Treg cells can interfere with effector T cells by IL-2 
consumption. Moreover they can cause cell apoptosis in a granzyme and perforin-dependent 
manner.  
CTLA4 (Cytotoxic T lymphocyte antigen 4) was shown to be an important inhibitory 
molecule (Lin et al. 1998). Treg cells can also prevent effector T cellactivation by inhibiting 
dendritic cells (DCs) by binding of CTLA-4 to CD80/CD86 (DC activation markers).  
Another suppression mechanism is through, LAG3 (Lymphocyte-activation gene 3), 
selectively expressed on Tregs, binds to MHC class II on DCs leading to DC functional 
impairment (Vignali et al. 2008; Shevach, 2009; Josefowicz, 2012). Mice studies on LAG 3 
have shown that antibodies to LAG-3 inhibit suppression by induced Tregs both in vitro and 
in vivo (Huang et al. 2004).  
On the other hand GITR (glucocorticoid-induced tumor-necrosis-factor-receptor-related 
protein) is constitutively expressed in high levels in Tregs (Ephrem et al. 2013). Initially, it 
was proposed that the main effect of GITR was the dowregulation of Treg-cell activity, 
however new studies have shown that GITR is important for the stimulation of effector T cells 
(Shevach et al. 2006) 
 
 
1.2.3 The relevance of Th1, Th2 and regulatory T cells in allergic diseases 
 
In a first, sensitization phase, dendritic cells capture, process and present the allergen to naïve 
T cells which differentiate to Th2 cells. These allergen-specific Th2 cells then enter clonal 
expansion and produce pro-inflammatory cytokines which trigger the production of IgE by B 
cells. Allergen-specific IgE binds to mast cells and basophils. Simultaneously there is the 
development of antigen memory with the production of allergen-specific memory B and T 
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cells. The second, effector phase, occurs during repeat d exposure to the same allergen. The 
allergen binds and cross-links the specific IgE displayed on sensitized mast cells and 
basophils, leading to their activation and secretion of immune mediators (Palomares t al. 
2010). To counteract the exacerbate immune responses, Tr g cells with inhibitory properties 
are expanded (Palomares t al. 2010; Barnes, 2008). 
Th2 cells have the ability to produce (and to be activ ted by) IL-4 and IL-13 which influences 
the regulation of IgE production. Furthermore IL-5 production by Th2 cells is important for 
the recruitment and differentiation of eosinophils (Maggi, 1998). Studies have shown more 
Th2 cells in the airways of asthmatics (Robinson et al. 1992; Bentley et al. 1992) as well as 
increased IL-4, IL-5, IL-13 and IL-10 levels in the skin of atopic dermatitis patients and a 
positive association of IL-5 and IL-13 with IgE levels in those patients (Jeong et al. 2003). 
Due to their importance in inflammatory processes, Th2 imbalance promoted by genetic 
alterations was shown to be a relevant element for the study of allergic diseases. Two 
transcription factors are important in Th2 and IgE regulation, GATA3 and STAT6 (Figure 1). 
In a mouse model, STAT6 knock-out was shown to result in reduced IL-4 mediated functions, 
such as Th2-differentiation and IgE class switching (Takeda et al. 1996; Shimoda et al. 1996).  
Human studies revealed that genetic changes like single nucleotide polymorphisms (SNPs) in 
the STAT6 gene were associated with IgE levels in different populations of children and adults 
(Schedel et al. 2004, Duetsch et al. 2002; Weidinger et al. 2004; Weidinger et al. 2008). 
Th1 cells also play an important role in allergic diseases as IFN-γ suppresses Th2 cells. 
Decreased IFN-γ in neonates was associated with a higher risk of developing atopic dermatitis 
during the first 2 years of life (Herberth et al. 2010).  
TBX21 and HLX1 play a major role in controlling Th1 lineage (Figure 1) and polymorphisms 
in these transcription factors were reported to affect asthma risk in children (Suttner t al. 
2009; Suttner et al. 2009). 
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Figure 1. T cells are characterized by their transcription factors as well as different cytokine secretion patterns.  
 
 
Due to their ability to control effector T cell responses, Treg cells play a major role in the 
development and maintenance of autoimmune and allergic diseases. Their importance has 
been confirmed by mouse studies, reporting that depletion of Treg cells during the priming 
phase of an active immune response led to a dramatic exacerbation of allergic airway 
inflammation (Baru et al. 2010) and worsened allergic airway hyperreactivity (Suto et al. 
2001).  
Treg cells have been shown to be impaired in pediatric sthma (Hartl et al. 2007) and in 
children with egg allergy (Smith et al. 2008). Furthermore, neonates from atopic mothers (a 
risk factor for atopic diseases) showed decreased Tr g cell numbers and function at birth 
(Schaub et al. 2008). 
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1.3 THE ROLE OF ENVIRONMENTAL AND GENETIC FACTORS I N ALLERGIC 
DISEASES 
 
1.3.1 Impact of the environment on allergic disease 
 
In the last decades, in parallel to the increasing number of people suffering from allergic 
diseases, major changes have been observed in lifestyle, particularly in industrialized 
countries (Masoli et al. 2004; von Mutius, 2000).  
The relationship between a “traditional” lifestyle and lower prevalence of allergies and 
asthma has been consistently demonstrated in several epidemiological studies in different 
countries and both in children and adults (von Mutius, 2008).  
Children from farming households in areas of Austria, Germany and Switzerland were shown 
to have lower prevalence of hay fever, atopic sensitization and atopic asthma (Braun-
Fahrländer et al. 2002). In accordance, it was shown in Australia that children who have lived 
on a farm were less prone to develop atopy (Downs et al. 2001).  
Identification of specific exposures such as endotoxin levels (Braun-Fahrländer et al. 2002), 
contact to different animal species (Remes et al. 2003, Ege et al. 2006), consumption of farm 
milk (Perkin, 2006; Riedler et al. 2001; Loss et al. 2011; Waser et al. 2007) and microbial 
diversity (Ege et al. 2011) have been shown to be particularly important for the allergy  
protective effect (Lluis, Schaub, 2012). 
Involvement of innate receptors, CD14 and TLR2 (Launer, 2002) and of regulatory T cells 
(Schaub et al. 2009) have been demonstrated. However the exact mehanisms of how the 
environment changes allergic disease susceptibility are still unknown.  
Furthermore, it seems that the modulation of the immune system through external exposures 
may start already in utero (Douwes et al. 2008; Schaub et al. 2009, Ege et al. 2006).  
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This concept of rural and farm environments providing protection against allergic disease 
development is in sync with the theory of the “hygiene hypothesis”. This concept was 
proposed in 1989 by Strachan (Strachan, 1989) and described that family size was inversely 
related to allergic diseases. This finding led to the speculation that lower allergy prevalence 
could be related to a higher rate of infections transmitted by the older siblings.  
The idea then extended to environmental factors like higher intake of antibiotics and 
vaccination, better hygiene, sew system, clean water (Bloomfield et al. 2006; Weiss, 2002) 
 
1.3.2 The influence of genetics for disease predisposition 
 
Despite the understanding of the environmental protective factors for the development of 
allergic diseases, it is important to consider that not all children living under a “risk” or 
“protective” environmental conditions will develop or not develop allergic diseases. Allergic 
diseases are a complex result from the interaction of individual genetic susceptibility and 
environmental exposures.  
Large genetic studies such as Genome-wide association study (GWAS) have been extremely 
valuable in identifying susceptibility loci for allergic diseases (Tamari et al. 2013). In this 
context, more functional assays and pathway studies ar  still needed to understand the 
underlying pathophysiological mechanisms (Tamari et al. 2013, Vercelli, 2008; Holloway et 
al. 2010). 
According to Vercelli, there are four main groups of genes associated with asthma, the ones 
associated with (Vercelli, 2008):  
 Innate immunity and immunoregulation 
 Th2 differentiation and effector functions 
 Epithelial biology and mucosal immunity 
 Lung function, airway remodeling and disease severity  
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In regards to Th2 differentiation, polymorphisms in GATA3, TBX21, IL-4, IL4RA35, STAT6 
and IL12B have been associated with asthma and allergy (Vercelli, 2008). It is important to 
note that Th2-related polymorphisms also influence further pathways such as IgE 
amplification, dependent on Th2 cytokines expressed by basophils and mast cells (Vercelli, 
2008). 
A focus on gene-environment interactions is also necessary, using both in vitro and in vivo 
models and epidemiological studies. 
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1.4 AIM OF THE STUDY 
Early life immune modulation is an extremely relevant window period for the development of 
allergic diseases. Important Th1 and Th2-associated genetic alterations have been associated 
with disease development in German school-age (9-11 years) children (Schedel t al. 2004, 
Suttner et al. 2009, Suttner et al. 2009). Nevertheless, up to date, no studies were conducted 
to examine whether those genetic changes can already mo ulate the immune system at birth, 
and how that relates to early allergic disease development during the first years of life. 
Moreover it is known that farm exposures influence regulatory T cells at birth (Schaub et al. 
2009) and early childhood (4.5 years) (Lluis, Depner et al. 2013), still no data are available in 
regards to the effect of farm on regulatory T cells with continuous immune maturation. 
 
 
This work aimed to investigate whether:  
 Th1 and Th2 polymorphisms which were previously associated with the development 
of allergic diseases in German school-age children, are associated with changes with 
immune responses already at birth – (cord blood stuy) 
 Neonatal immune responses modulated by polymorphisms are associated with allergic 
and respiratory disease development during the first 3 years of life 
 Regulatory T cells are modulated (in number and suppressive capacity) by farm-
associated exposures such as contact to hay, to stables, farm milk consumption in 
children at age of 6 years 
 Regulatory T cells participate in the protective farm effect against the development of 
allergic diseases at age 6 years  
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2. Materials and Methods 
2.1 MATERIALS 
 
Reagents and chemicals  
 
 
100bp ladder (500μg/mL)  New England BioLabs, Ipswich, USA 
ACK Lysis Buffer Cambrex, East Rutherford, USA 
Anti-human CD3-PE antibody  Beckmann Coulter, Fullerton, USA 
Anti-human CD4-FITC antibody BD Pharmingen, Franklin Lakes, USA 
Anti-human CD4-FITC antibody Beckmann Coulter, Fullerton, USA 
Anti-human CD25-APC antibody  BD Pharmingen, Franklin Lakes, USA 
Anti-human CD25-PC5 antibody Beckmann Coulter, Fullerton, USA 
Anti-human CD127-PE antibody eBioscience, San Diego, USA 
Anti-human FOXP3-PE antibody  BD Pharmingen, Franklin Lakes, USA 
Anti-human FOXP3-PE antibody  eBioscience, San Diego, USA 
Anti-human IgG1-FITC antibody  Dako Cytomation, Glostrup, Denmark 
Anti-human IgG1-PE antibody BD Pharmingen, Franklin Lakes, USA 
Anti-human IgG1-PE antibody Dako Cytomation, Glostrup, Denmark 
Anti-human IgG2a-PC5 antibody Beckmann Coulter, Fullerton, USA 
Anti-human IgG2a-PE antibody eBioscience, San Diego, USA 
Bioplex Sheath Fluid Biorad, Hercules, USA 
Boric acid Sigma-Aldrich, Steinheim, Germany 
Bovine Serum Albumin (BSA)  Sigma-Aldrich, Steinheim, Germany 
Bromophenol blue Roth, Karlsruhe, Germany 
D. pteronyssinus allergen 1 (Derp1) Indoor Biotechnologies, Charlottesville, USA 
Ethanol 100 % Merck, Darmstadt, Germany 
Ethidiumbromide (10mg/mL) Biorad, Hercules, USA 
Ethylene diamine tetraacetic acid EDTA (0.5M) Sigma-Aldrich, Steinheim, Germany 
FACS Clean Solution BD Biosciences, Heidelberg, Germany 
FACS Flow™ Sheath Fluid BD Biosciences, Heidelberg, Germany 
FACS Rinse Solution BD Biosciences, Heidelberg, Germany 
Ficoll-Paque™ PLUS GE Healthcare, Piscataway, USA 
Fixation/Permeabilization Concentrate eBioscience, San Diego, USA 
Fixation/Permeabilization Diluent eBioscience, San Diego, USA 
Fluorescein Calibration Dye Biorad, Hercules, USA 
Fetal Bovine Serum Gold (FCS) PAA Laboratories GmbH, Pasching, Austria 
Glycerol Sigma-Aldrich, Steinheim, Germany 
H2O bidest H. Kerndl GmbH, Weißenfeld, Germany 
Human serum Sigma-Aldrich, Steinheim, Germany 
Ionomycin Sigma-Aldrich, Steinheim, Germany 
Isopropanol 100 % Merck, Darmstadt, Germany 
LiChrosolv H2O (HPLC) Merck, Darmstadt, Germany 
Liquemin N 7500 (Na-Hep) Roche Diagnostics, Mannheim, Germany 
Lipid A  Sigma-Aldrich, Steinheim, Germany 
Lipopolysaccharide Sigma-Aldrich, Steinheim, Germany 
Nuclease-free water Ambion, Austin, USA 
Paraformaldehyde Sigma-Aldrich, Steinheim, Germany 
PBS with EDTA (2mM) Apotheke Innenstadt Uni München, Munich, Germany 
Penicillin/Streptomycin Gibco, Carlsbad, USA 
Peptidoglycan Sigma-Aldrich, Steinheim, Germany 
Permeabilization Buffer (10X) eBioscience, San Diego, USA 
Phosphate-Buffered Saline (PBS)   Gibco, Carlsbad, USA
Phorbol 12-myristate 13-acetate (PMA) Sigma-Aldrich, Steinheim, Germany 
Phytohemagglutinin Sigma-Aldrich, Steinheim, Germany 
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Primers  Invitrogen, Carlsbad, USA 
Rat serum eBioscience, San Diego, USA 
RPMI 1640 + GlutaMax Gibco, Carlsbad, USA 
Sodium hydroxide (NaOH) Sigma-Aldrich, Steinheim, Germany 
Trypan Blue Sigma-Aldrich, Steinheim, Germany 
TRIzol Reagent  Invitrogen, Carlsbad, USA 
Tween 20 Merck, Darmstadt, Germany 
Water DEPC (0.1 %) Serva Electrophoresis GmbH, Heidelberg, Germany 
Water, Mol Bio grade 5 Prime, Gaithersburg, USA 
     
  
    
  
 
 
Solutions and buffers 
 
 
1% PFA  10g paraformaldehyde 
 Ad 900mL ddH2O 
 800μl 1N NaOH 
 30 min at 65°C 
 100mL PBS 10X until pH 7.4 
5.5 % BSA 5.5g Bovine Serum Albumin 
 100mL PBS with EDTA (2mM) 
5X TBE buffer 54g Trizma Base 
 27.5g boric acid 
 20mL 0.5M EDTA (pH 8.0) 
 Ad 1l H2O bidest. 
DNA ladder  10μl 100bp ladder 
 80μl 0.5x TBE-Buffer 
 10μl Loading Dye 
Ethidiumbromide (500μg/mL) 100μl Ethidiumbromide 
 1900μl dH2O  
FACS buffer 25mL 10X PBS 
 Ad 250mL LiChrosolv H2O 
 12.5mL FCS (5 %) 
 1.25mL Tween 20 (0.5 %) 
Isolation buffer (0.55% BSA) 40mL PBS with EDTA (2mM) 
 4mL 5.5 % BSA  
Loading dye diluted solution 5mL Loading dye stock solution 
 13.5mL glycerol 
 31.5mL dH2O 
Loading dye stock solution 0.25g bromophenol blue 
 0.25g xylene cyanol 
 30 % glycerol 
 70mL dH2O 
Medium 10 % human serum 440mL RPMI 1640 + GlutaMAX 
 10mL Penicillin/Streptomycin 
 50mL inactivated human serum 
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Reagent systems (Kits) 
 
 
Allergy Screen test panel for atopy Mediwiss Analytic, Moers, Germany 
CellTrace™ CFSE Cell Proliferation Kit  Invitrogen, Carlsbad, USA 
CD3 MicroBeads Miltenyi Biotec, Bergisch Gladbach, Germany 
CD4+CD25+ Regulatory T Cell Isolation Kit Miltenyi Biotec, Bergisch Gladbach, Germany 
  
FlexiGene DNA Kit Qiagen, Hilden, Germany 
Human Cytokine Multiplex Assay Kit  Biorad, Hercules, USA 
Human FoxP3 Buffer Set BD Pharmingen, Franklin Lakes, USA 
Roche LightCycler® 480 Probes Master Roche Diagnostics, Mannheim, Germany 
SYBR Green PCR Master Mix Applied Biosystems, Foster City, USA 
   
     
  
     
  
Consumables 
 
Filter Mat Glass Fiber Paper Skatron Instruments, Lier, Norway 
iQ™ 96-Well PCR Plates   Biorad, Hercules, USA 
Biosphere® filter tips 10µL M 40mm type D Sarstedt, Nümbrecht, Germany 
Biosphere® filter tips 100µL   Sarstedt, Nümbrecht, Germany 
LD columns  Miltenyi Biotec, Bergisch Gladbach, Germany 
LS columns Miltenyi Biotec, Bergisch Gladbach, Germany 
Microtest™ 96 well plates  BD Biosciences, Heidelberg, Germany 
MS columns Miltenyi Biotec, Bergisch Gladbach, Germany 
Multiwell™ 6 well plates BD Biosciences, Heidelberg, Germany 
SafeGuard Filter tips 100-1000µL Peqlab, Erlangen, Germany 
Serum-Gel S-Monovette Sarstedt Nümbrecht, Germany 
 
  
   
    
    
Additional laboratory equipment 
 
 
Centrifuge 5810 R / 5417 R / 5415 R Eppendorf, Hamburg, Germany 
Centrifuge Rotanta 460R / S Hettich, Tuttlingen, Germany 
Combi cell harvester Skatron Instruments, Lier, Norway 
Electrophoresis Power Supply VWR International, Radnor, USA 
FACS MoFlo XDP  Beckman Coulter, Fullerton, USA 
FACSCalibur  Becton-Dickinson, Heidelberg, Germany 
FACSCanto II  Becton-Dickinson, Heidelberg, Germany 
Gel iX Imager  Intas Science Images Instruments, Göttingen, 
Germany 
iCycler iQ™ Real Time PCR Detection System Biorad, Hercules, USA 
Incubator Hera Cell 240 Hereus, Hanau, Germany 
Incubator Heraeus 6000  Heraeus, Hanau, Germany 
LUMINEX 100 IS System Luminex Corp., Austin, USA 
MACS® MultiStand Miltenyi Biotec, Bergisch Gladbach, Germany 
Micro Centrifuge II NeoLab, Heidelberg, Germany 
Microplate shaker Type Rotamax 120 Heidolph Instruments, Schwabach, Germany 
Microscope Axiovert 40C Zeiss, Göttingen, Germany 
Microwave Siemens, Munich, Germany 
MidiMACS™ Separator Miltenyi Biotec, Bergisch Gladbach, Germany 
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MiniMACS™ Separator  Miltenyi Biotec, Bergisch Gladbach, Germany 
Neubauer cell counter Karl Hecht KG Assistent, Sondheim, Germany 
Owl D3-14 Wide Gel System Thermo Scientific, Waltham, USA 
Roche LightCycler 480 System Roche Diagnostics, Mannheim, Germany 
Sterile Hood LaminAir HBB2472  Heraeus, Hanau, Germany 
Thermocycler Eppendorf Mastercycler Eppendorf, Hamburg, Germany 
Vacuum regulator Biorad, Hercules, USA 
Vortex Genie 2 Scientific Industries, Bohemia, USA 
Waterbath Köttermann   Köttermann GmbH, Uelze, Germany 
    
    
     
     
Software 
 
 
Adobe Photoshop  Adobe Systems, Edinburgh, UK 
Bio-plex Manager Software 4.1 Biorad, Hercules, USA 
Cell Quest Software Becton-Dickinson, Heidelberg, Germany 
Cell Quest Pro Software  Becton-Dickinson, Heidelberg, Germany 
EndNote X3/X4  ISI ResearchSoft, Berkeley, USA 
Ensembl Genome Browser http://www.ensembl.org/ 
FACSDiva software Becton-Dickinson, Heidelberg, Germany 
FCS express v3/v4 De Novo Software, Los Angeles, USA 
Haploview http://www.broad.mit.edu/mpg/haploview/ 
iCycler iQ Optical System Software v3.1 Biorad, Hercules, USA 
Microsoft Office  Microsoft, Redmont, USA 
National Center for Biotechnology Information http://www.ncbi.nlm.nih.gov/ 
Sigmastat version 1.0  Systat Software Inc., Chicago, USA 
SPSS version 20  SPSS IBM Inc., Armong, USA  
WinMDI 2.8  The Scripps Research Institute, La Jolla, USA 
  
  
     
  
   
    
      
  
     
 
 
 
MATERIALS AND METHODS 
 
18 
 
2.2 METHODS 
 
2.2.1 Cord blood studies 
 
2.2.1.1 Study Population 
Between July 2005 to September 2007 pregnant women were approached for the study’s 
recruitment during their last trimester of pregnancy. The recruitment took place in the Munich 
metropolitan area, Germany.   
Participants were excluded in case of preterm deliveries, multiple gestations, perinatal 
infections, fever around birth, maternal intake of medication and maternal chronic diseases 
(Schaub et al. 2009; Schaub et al. 2008; Casaca et al. 2012, Casaca et al. 2013). A total of 
200 neonates took part in the study. 
All mothers answered comprehensive questionnaires which included assessment of potential 
covariates such as sex, smoking, birth characteristics, race/ethnicity, siblings, education, 
previous cesarean section and miscarriage. Written informed consent was obtained from all 
mothers. Ethical approval for the study was obtained from the local human research 
committee of the Bavarian Ethical Board, LMU Munich, Germany (Casaca et al. 2013). 
 
2.2.1.2 Definition of clinical phenotypes 
Doctor’s diagnosis of asthma and/or eczema and/or hay fever was documented by personal 
interview and defined the maternal atopic status. Furthermore, maternal sera were used to 
measure total and specific maternal IgE levels by RAST (radioallergosorbent test). A positive 
specific IgE was defined as 1 or more positive reactions ≥ 0.35 IU/ml to a panel of common 
allergens: aeroallergens (mites, Dermatophagoides pteronyssinus and Dermatophagoides 
farinae, birch pollen, hazelnut pollen, timothy grass, mugwort, plantain), animals (cat, horse, 
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dog), Alternaria, and food including egg white, milk protein, peanut, hazelnut, carrot, wheat 
flour and soy as previously described by Schaub et al. (Schaub et al. 2008).  
From the mothers defined as atopic, 82.6 % were confirmed to have a positive RAST test, 
while non-atopic mothers had no atopic disease and sensitization levels comparable to 
previous epidemiological studies among non-diseased subjects (Heinrich et al. 2002).  
When the children turned 3 years, parents completed detailed questionnaires assessing allergic 
and respiratory diseases: obstructive bronchitis wa defined as a doctor’s diagnosis of asthma 
ever or a repeated diagnosis of obstructive bronchitis; food allergy as clinical symptoms or as 
doctor’s diagnosis of food allergy; atopic dermatitis (AD) as doctor’s diagnosis of AD and 
wheeze was defined by airway obstructive symptoms from birth until the age of 3 years. 
 
2.2.1.3 Cell isolation and culture 
Umbilical blood was collected immediately after deliv ry. Blood was collected into sodium 
heparin or EDTA tubes. Within 24 h after delivery, EDTA tubes were frozen until DNA 
extraction. DNA was extracted using the FlexiGene DNA kit (Qiagen, Hilden, Germany) 
according to the manufacturer’s instructions.  
Sodium heparin tubes were processed within 24 h for isolation of cord blood mononuclear 
cells (CBMCs). CBMCs were isolated by density gradient Ficoll-HypaqueTM PLUS (GE 
Healthcare, Piscatay, USA). Cells were stimulated for 3 days with Lipid A (LpA, 0.1μg/ml), 
Peptidoglycan (Ppg, 10μg/ml), the allergen house dust mite (Derp1, 30μg/ml), a combination 
of Derp1 and LpA (D+L) or cultured without stimulation. After 3 days cells were collected 
for mRNA extraction, cytokine measurement and flow cytometry. 
 
2.2.1.4 Cytokine secretion 
Supernatants were used for measurement of cytokines including: IFN-γ, IL-5, IL-6, IL-13, 
GM-CSF and TNF-α. Cytokines were measured by Human Cytokine-Multiplex-Assay-Kit 
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(Bio-Rad, Munich, Germany) according to the manufacturer’s instructions. The limits of 
detection (pg/ml) were as follows: 1.3 (IFN-γ), 1.8 (IL-5), 0.5 (IL-6), 2.1 (IL-13), 1.0 (GM-
CSF) and 3.0 (TNF-α). 
 
 
2.2.1.5 Flow cytometry 
For the assessment of activated T cells (CD4+CD25+) a 3-color flow cytometer (FACScan; 
BD Biosciences, Heidelberg, Germany) was used. Cells were incubated with 2 µl of anti-
human CD4–fluorescein isothiocyanate (FITC) and 1 µl of CD25–RPE-Cy5 (Dako 
Cytomation, Glostrup, Denmark). For isotype control 1 µl of IgG1-FITC (Dako Cytomation) 
and 0.5 µl of IgG2a RPE-Cy5 (BD Biosciences) were us d (Schaub et al. 2009). The flow 
cytometry data were analyzed using CellQuest software (BD Biosciences) and post-
acquisition analysis was performed with WinMDI 2.8 software (The Scripps Research 
Institute, La Jolla, CA). 
 
 
2.2.1.6 Polymorphisms’ selection and genotyping   
The Th1 and Th2 cell lineage polymorphisms selected for this study were based on previous 
reports that showed their putative functional importance and an association with disease 
development or IgE levels in German children (9-11 years old) and other study populations 
(Suttner et al. 2009; Suttner et al. 2009; Schedel et al. 2004; Schedel et al. 2009; Weidinger et 
al. 2004). 
The following polymorphisms were chosen: Th2 STAT6 rs1059513 and rs324011 and Th1 
TBX21 rs17250932 and rs11079788 and HLX1 rs2738751, rs3806325 and rs12141189.  
The genotypes of STAT6, TBX21 and HLX1 were determined by Matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS, Sequenom Inc., 
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San Diego, CA, USA). SpectroDESIGNER software (Sequenom Inc.) was used to design 
polymerase chain reaction assays and associated extnsion reactions. Amplification and 
extension reaction conditions were previously described (Schedel et al. 2004; Casaca et al. 
2013).  
 
 
2.2.1.7 Quantitative Real-Time-PCR 
Total RNA was isolated with TRI reagent from CBMCs after 72 h of incubation with LpA, 
Ppg, Derp1, D+L or from unstimulated cells. RNA was reverse transcribed into cDNA 
following manufacturer’s instructions (Invitrogen, Karlsruhe, Germany).  
Forward and reverse primers for the housekeeping gene 18SrRNA, Treg-related FOXP3, 
LAG3, GITR, Th2-related STAT6, STAT6d, STAT6e, GATA3, Th1-related TBX21, HLX1, 
IRF1, Th17-related IL-22 and Th9-related IL-9 genes were designed with Vector NTI advance 
10 (Invitrogen, Karlsruhe, Germany). Gene expression was measured by the increase in 
fluorescence caused by the binding of SYBR Green to double stranded DNA. Normalization 
of the values was done by subtracting the corresponding 18S RNA threshold cycle (Ct) value 
from the Ct of the gene of interest: ΔCt = Ct (gene of interest) - Ct (housekeeping gene). 
Higher ∆Ct represents a lower gene expression and vice-versa (Casaca et al. 2012; Casaca et 
al. 2013). The housekeeping gene was previously by lab work as it was shown to be have a 
stable profile independent of stimulation. All primers were tested for specificity. 
 
2.2.1.8 Statistical analyses  
Data were generally reported in 3 group comparisons including the health outcomes in the 3 
year follow-up. The non-parametric Kruskal-Wallis test was applied to analyze cytokine 
secretion as data were generally not normally distributed and could not be transformed to 
normality. The value of 0.01 was assigned to undetectable cytokine concentrations so that the 
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undetectable values could be included in the analysis. Gene expression data were also 
analyzed with Kruskal-Wallis test. Immunological data were shown as medians, first and third 
quartiles.  
Results were further analyzed using genetic models, r cessive or dominant models, and 
differences were tested with Wilcoxon test. Dominant model compares wildtype vs 
heterozygous and SNP homozygous and the recessive mod l compares SNP homozygous vs 
heterozygous and wildtype. 
Correlation of gene expression and cytokine secretion were assessed by Spearman correlation 
coefficients. Differences were considered significant with p ≤ 0.05 or as borderline significant 
with p ≤ 0.1. 
As expression of the Treg-related gene markers FOXP3, GITR and LAG3 was correlated with 
each other and also pro-inflammatory and Th2 cytokines were correlated, data were not 
adjusted for multiple testing. 
Mantel–Haenszel test was used to test differences in the health outcomes between the groups.   
In total 200 children participated in the study; however the number for single analyses varied 
due to sample availability or non-participation in the follow up at age 3 years.  
Statistical analyses were performed by SAS (version 9.2, SAS Institute, Cary, NC, USA).  
(Casaca et al. 2013). 
 
 
 
Of note: The cord blood samples were collected betwe n 2005 and 2007 and processed 
freshly. During my thesis the samples had been measur d and my worked was focused in 
gathering the data and analysis. However for the reader’s understanding, the lab techniques 
were described in the Methods. 
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2.2.2 PASTURE/EFRAIM study 
 
2.2.2.1 Study population 
The PASTURE (Protection against allergy: study in rural environments) study and the follow-
up study EFRAIM (Mechanisms of Early Protective Exposures on Allergy Development) is a 
large international birth cohort study that includes children from 5 European countries: 
Austria, Finland, France, Germany and Switzerland (von Mutius et al. 2006) to investigate the 
protective factors against the development of allergies in early life. 
The PASTURE/EFRAIM cohort comprises more than 1000 children.  For the investigation of 
this thesis a subgroup of 143 German children with available Treg cell data were followed 
until age 6 years. 
Initially, women who lived in rural areas were recruited: women who lived on family-run 
livestock farms were considered as farming mothers and women not living on a farm, but 
from the same rural areas as non-farming mothers. The study was approved by the local 
research ethics committee and informed consent was obtained from all parents (von Mutius et 
al. 2006). 
 
2.2.2.2 Assessment of farm exposures  
Parents completed several questionnaires overtime: wh n the children were 2, 12, 18, 24, 36, 
48 months, 4.5 and 6 years. 
The questions were based on previous studies: the ALEX (Allergy and Endotoxin Study) 
(Riedler et al. 2001), the AMICS (Asthma Multicenter Infants Cohort Study) (Basagana et al. 
2002), the PARSIFAL study (Prevention of Allergy Risk factors for Sensitization In children 
related to Farming and Anthroposophic Lifestyle) (Alfven et al. 2006) and questions derived 
from the ATS (American Thoracic Society) questionnaire (Ferris, 1978). The questionnaires 
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inquired about the general health of the child and family and detailed farm exposures. A child 
was defined as farm child if he/she lived on a farm.  
Farm milk consumption was defined if the child drank any farm milk within the last 12 
months prior to the questionnaire or whether the mother drank farm milk during pregnancy. 
Contact to hay was defined by children who had regular contact to hay, at least once a week. 
Stable exposure defined children which regularly spent time in the stable of their own or 
another farm. Both exposures were assessed in regards to the last 12 months. A single contact 
to the stable was enough to classify them as children with stable contact (Lluis, Depner, t al. 
2013). 
 
2.2.2.3 Clinical phenotypes 
The asthmatic group at age 6 years included children that had a life time prevalence of a 
doctor’s diagnosis of asthma ever and/or a repeated diagnosis of obstructive bronchitis and/or 
children which are intermediate, late onset and persistent wheezers after the first 6 years 
and/or children with wheeze without a cold and sympto s between wheeze from age 18 
months to age 6 years. Current asthma defines children with a doctor diagnosis of asthma ever 
and any wheeze episodes in the last year. 
Specific IgE was measured in sera at age 6 years of the children to assess allergic 
sensitization. Allergens tested included: food allergens, hen’s egg, cow’s milk, peanut, 
hazelnut, carrot and wheat flour; and inhalant allergens, D. pteronyssius, D. farinae, cat, 
horse, dog, Alternaria, mugwort, plantain, alder, birch pollen, hazel pollen, rye pollen, and a 
grass pollen mix.  
Sensitization against food or inhalant IgE were asses ed using three RAST class cut-offs: 
Class I ≥ 0.35 IU/ml; Class II ≥ 0.7 IU/ml and Class III ≥ 3.5 IU/ml.  
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2.2.2.4 Isolation of peripheral blood mononuclear cells  
Peripheral blood was collected in sodium heparin tubes and peripheral blood mononuclear 
cells (PBMCs) were isolated within 24 hours using density gradient centrifugation (Ficoll-
Paque™ PLUS). Cells were washed with RPMI 1640 + GlutaMax and counted. 
 
2.2.2.5 Culture for Treg cell frequency assessment  
PBMCs were set to the final concentration of 5x106cells/ml in RPMI with 10 % human serum 
and incubated for 24 h, at 37°C with 5 % CO2 with no addition of stimulus (control - media) 
or with PMA (5 ng/ml) and Ionomycin (1 µg/ml) or lipopolysaccharide (Lps, 0.1 µg/ml). 
After 24 h cells were washed and stained for flow cytometry  
 
2.2.2.6 Treg frequency assessment  
For Treg cell frequency assessment, cells were harvested after 24 h and diluted in 5 ml RPMI 
for counting. Cells were resuspended at final concentration of 1x107 cells/ml in RPMI and 
incubated with 8 µl of CD4-FITC, 4 µl of CD25-PE for surface staining markers. The cells 
were then fixed and permeabilized (Human FoxP3 Buffer Set, BD Pharmingen, Franklin 
Lakes, USA) before addition of 5 µl of FOXP3-PE. The isotypes used were: IgG1 FITC, 
IgG2a PC5 and IgG2a-PE. Treg cells were defined as the CD4 positive cell expressing high 
levels of CD25 (upper top 20 %) and FOXP3 (figure 5). 
 
2.2.2.7 Cell isolation for Treg functional assay 
To isolate the different cell subtypes (antigens presenting cells, effector T cells and Treg cells) 
a magnetic bead system was used. PBMCs were resuspended in autoMACS® Running 
Buffer. Approximately 2x106 cells were taken for CD3-marker isolation and the remaining 
was used for CD4 isolation. For CD3 isolation CD3 microbeads were added and incubated for 
15 min at 4º C before separation in the autoMACS Pro Separator. CD3- cells  (APCs) were 
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resuspended at the final concentration of 8x105 cells/ml in RPMI with  Human serum 10 % 
and irradiated at 30Gy (3000rad) for 10 min. CD3+ fraction was used for isotype and 
compensation controls. For CD4+ cell isolation 10 µL per 10x107 cells of Biotin-Antibody 
Cocktail was added and mixed. 20 µL of Anti-Biotin MicroBeads were added following 
additional 15 min of incubation at 4 °C. CD4+ cells were resuspended in 90 µL of buffer and 
used for effector and Treg cell isolation. 10 µL of CD25 MicroBeads were added and cells 
were incubated for 15 min at 4°C.  
CD4+CD25+(high) (Treg cells) were washed and resuspended at 4x105 cells/ml in RPMI with 
Human serum 10 % and CD4+CD25- (effector cells) were labelled with CD25 microbeads for 
a second round of isolation to increase the purity. The second CD4+CD25- fraction was 
washed and resuspended in 1 ml of PBS/10 % FCS for CFSE staining.  
After incubation with the antibodies, cells were washed and resuspended in FACS buffer and 
cell purity was measured by flow cytomery in FACSCanto II. 
 
2.2.2.8 CFSE staining of CD4+CD25- cells  
For preparation of 5 mM CellTrace™ CFSE stock soluti n the content of component A 
(CellTrace™ CFSE) was dissolved in 18 μL of the DMSO provided (Component B). 5 μl of 
A+B were added to 5 ml of PBS/10 % FCS and 1 ml wastaken and added to the cells. Cells 
were incubated for 5 min in the dark and then washed 3x (10 min) with PBS/10 % FCS. Cells 
were then resuspended in 2 ml of RPMI with 10 % Human serum for 1-2 h at 37 °C. 
Afterwards, cells were resuspended at 4x105cells/ml in RPMI with Human serum 10 %. 
 
2.2.2.9 Cell culture for Treg functional assay 
For the determination of Treg suppressive capacity co-cultures were performed as follows: 
CFSE-treated CD4+CD25- cells (2x104 cells/well) were incubated with irradiated CD3- cells 
(4x104 cells/well), with or without CD4+CD25high T cells at the ratios CD4+CD25-/ 
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CD4+CD25high, 1:0.5 or 1:0.25. For stimulation, PHA 0.8 µg/ml was used. Cells were 
incubated in a 96-round bottom well plate for 3 days t 37 °C with 5 % CO2. After culture 
cells were harvested and the supernatants collected for cytokine measurement.  
 
2.2.2.10 Treg functional assay assessment 
For Treg suppressive capacity, cells were harvested aft r 72 hours, counted and resuspended 
in 50 µl of FACS buffer. 2 µl of CD4-APC-H7 and 2 µl CD25-PE were added for 10 minutes. 
Cells were then washed and resuspended in FACS buffer for purity measurement in 
FACSCanto II. Immediately before measurement, 2 µl of PI were added for dead cell 
exclusion. Suppressive capacity was assessed by the division of CFSE-labelled effector cells 
(figure 6). 
 
2.2.2.11 Cytokine concentrations 
Cytokines were collected from the suppression assays cell cultures. The cytokines, IL-2, IL-5, 
IL-9, IL-10, IL-13 and IFN-γ were measured with the Human Cytokine-Multiplex-Assay-Kit 
according to the manufacturer’s instructions (Bio-Rad, Munich, Germany) by LUMINEX 
technology. The lower detection limits of the assay (pg/ml) were: 4.25 (IL-2), 0.24 (IL-5), 
0.21 (IL-9), 0.14 (IL-10), 0.17 (IL-13), 2.26 (IFN-γ) pg/ml.  
 
2.2.2.12 Statistical analyses 
Percentages of Treg cells were in relation to the lymphocyte gate defined through flow 
cytometry. Association of Treg cells and farm exposure  and clinical outcomes was analysed 
with the nonparametric Wilcoxon test. 
For Treg cell suppression data, before conducting statistical analysis, the data were log-
transformed to achieve normality. Data were close to normality to allow analysis with 
parametric test. Cytokine data distribution below the respective cytokine detection limit was 
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imputed according to Lubin (Lubin et al. 2004). Subsequently, a linear mixed model with 
varying intercept and slope was applied. Statistical significance was defined by a p-value ≤ 
0.05.  
Analyses were performed using SAS 9.2 (SAS Institute, Cary, USA) and R (R Core Team, 
2012).  
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3. Results  
 
3.1 IMPACT OF T CELL POLYMORPHISMS ON CORD BLOOD IM MUNE 
MODULATION AND ASSOCIATION WITH EARLY DISEASE DEVEL OPMENT 
 
Understanding the modulation of immune responses at birth is crucial as this is an important 
period in shaping the immune system. In 200 neonates, polymorphisms in Th1 and Th2 
transcription factors were investigated to assess their influence on neonatal immune responses 
and subsequent development of allergic and respiratory diseases during the first 3 years of 
life. Table I displays the study population characteristics. 
 
Table I. Cord blood study: population characteristics. 
 
Parameters n  N 
Female sex, n (%) 96 (48.0%) 200 
Gestational age, weeks, median (Q1;Q3) 40.0 (39.1;40.7) 200 
   
Maternal atopic diseases, n (%) 71 (35.5%) 200 
  Asthma, n (%) 14 (7.0%) 200 
  Hay fever, n (%) 52 (26.0%) 200 
  Atopic eczema, n (%) 16 (8.0%) 200 
  Maternal serum total IgE (IU/mL), median (Q1;Q3) 33.5 (13.1;87.3) 196 
  Maternal specific IgE >0.35 IU/mL, n (%) 83 (70.9%) 117 
Vaginal delivery, n (%) 177 (88.5%) 200 
Siblings ≥1, n (%) 89 (44.5%) 200 
   
Clinical outcome up to age 3 years, n (%)   
  Doctor’s diagnosis atopic dermatitis 26 (13.0%) 200 
  Doctor’s diagnosis food allergy 5 (2.5%) 200 
  Symptoms of food allergy 24 (12.0%) 200 
  Asthma/obstructive bronchitis 23 (11.5%) 200 
  Wheeze 75 (37.5%) 200 
Q1 = 1st quartile; Q3 = 3rd quartile. Total N = 200, total IgE measurements were available in 196 mothers and 
specific IgE in 117 mothers  (Casaca et al. 2013). 
 
 
 
As shown in Table II, a total of 7 polymorphisms were investigated: two in the STAT6 gene, 
two in TBX21 and three in HLX1. The minor allele frequencies (MAF) were generally 
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comparable to the MAF of the ISAAC study (Schedel et al. 2004, Suttner et al. 2009, Suttner 
et al. 2009). None of the polymorphisms significantly deviated from the Hardy-Weinberg 
equilibrium (HWE). 
 
Table II. Characteristics of the studied polymorphisms. 
 
 
Gene 
Rs 
number* 
Position in 
relation to 
1.ATG 
Position in the gene 
structure 
MAF 
(ISAAC†) 
MAF 
(our 
cohort) 
P value 
HWE 
Call rate 
STAT6 rs1059513 T12888C 3’ UTR 0.12 0.10 0.46 98.56 
STAT6 rs324011 C2892T Intron 2 0.37 0.38 0.93 98.85 
TBX21 rs17250932 T1514C Promoter 0.16 0.22 0.60 97.14 
TBX21 rs11079788 C9902T Intron 3 0.22 0.30 0.83 97.14 
HLX1 rs2738751 C1486G Promoter 0.14 0.15 0.88 97.14 
HLX1 rs3806325 C1407T Promoter 0.19 0.18 0.47 97.62 
HLX1 rs12141189 T346C Exon 1 0.25 0.25 0.40 97.62 
 
 
*SNP number according to database SNP (http://www.ncbi lm.nih.gov/snp). 
†ISAAC, International Study of Asthma and Allergy in Childhood phase II (school-age German children).  
MAF = Minor allele frequency, HWE = Hardy-Weinberg equilibrium. 
(Casaca et al. 2013). 
 
 
 
3.1.1 Modulation of neonatal immune responses by Th2 polymorphisms: STAT6 
 
3.1.1.1 Downregulation of Treg cell-related genes at birth is associated in carriers of 
STAT6 rs324011 polymorphism  
Carriers of STAT6 rs324011 had significantly decreased LAG3 mRNA expression upon 
Derp1-stimulation (p = 0.053, Fig. 2C). This pattern of downregulation was similar for 
FOXP3 and GITR mRNA-expression, although not significant:  FOXP3 (Ppg and Derp1-
stimulated, p = 0.063/ 0.063, Fig. 2A), GITR (Ppg, p = 0.095, Fig. 1B). LAG3 also showed a 
trend to lower expression in carriers of  rs324011 (unstimulated, p = 0.095 and LpA p=0.077, 
Fig. 1C) (Casaca et al. 2013). 
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As shown in Table III, applying the recessive model, the differences of lower FOXP3 
(unstimulated, Ppg, Derp1), GITR (Ppg) and LAG3-expression (unstimulated, LpA, Derp1) 
between the homozygous neonates and the heterozygous and wildtype became significant (p ≤ 
0.05) in comparison to the 3 group comparison analyses (Figure 2). 
No association was found for STAT6 rs1059513 polymorphism with expression of Treg cell-
related genes birth.  
STAT6 rs324011 and rs1059513 SNPs were further studied to assess whether they affected the 
expression of other Th-related genes in cord blood, including TBX21 and HLX1 (Th1), STAT6 
and two STAT6 isoforms (STAT6d, STAT6e) and GATA3 (Th2), IL-22 (Th22, Th17) and IL-9-
expression (Th9), however no significant differences were found (Casaca et al. 2013). 
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Figure 2. STAT6 rs324011 allele associated with downregulation gene expression of Treg cell-related markers.  
A) FOXP3; B) GITR; C) LAG3. Corresponding box plots represent mRNA expression in ∆Ct (normalized with 
18S); higher ∆ct represents lower mRNA expression and vice-versa. Data were shown as medians, first and third 
quartile. WT = wildtype, HT = heterozygous, SNP = SNP homozygous, U = Unstimulated, LpA = Lipid A, Ppg 
= Peptidoglycan, Derp1 = Dermatophagoides pteronyssinus. Data were analyzed with Kruskal-Wallis test. 
Maximum number for gene expression analysis: STAT6 rs324011 n (WT) = 43; n (HT) = 55; n (SNP) = 10.
(Casaca et al. 2013). 
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Table III. Dominant and recessive models comparing results of expression of Treg-related 
genes depending on STAT6 rs324011 genotypes.   
 
Parameter 
∆ct 
Stim. WT HT+SNP 
P value* 
Dominant† 
Foxp3 
U  
14.52 
(14.09-17.30) 
16.30 
(14.09-17.75) 
0.245 
LpA  
15.15 
(13.45-16.20) 
15.70 
(14.60-16.30) 
0.250 
Ppg  
14.90 
(13.45-15.90) 
15.00 
(13.20-16.20) 
0.596 
Derp1  
14.05 
(11.80-15.50) 
15.40 
(13.10-16.90) 
0.095 
GITR 
U  
14.28 
(14.28-16.85) 
16.05 
(14.28-17.63) 
0.311 
LpA  
15.18 
(12.50-16.80) 
16.00 
(14.90-16.85) 
0.121 
Ppg  
15.25 
(13.48-15.98) 
15.05 
(13.95-16.00) 
0.877 
Derp1  
13.80 
(11.75-15.50) 
15.50 
(12.40-16.20) 
0.227 
LAG3 
U  
16.36 
(15.93-19.05) 
17.50 
(15.93-19.40) 
0.587 
LpA  
16.70 
(14.90-18.05) 
17.65 
(15.85-19.05) 
0.233 
Ppg  
16.92 
(15.03-18.15) 
16.80 
(14.95-18.28) 
0.960 
Derp1  
14.75 
(13.00-17.75) 
16.90 
(14.43-18.15) 
0.100 
Parameter 
∆ct 
Stim. WT+HT SNP 
P value* 
Recessive† 
Foxp3 
U  
14.95 
(14.09-17.40) 
17.08 
(16.58-17.80) 0.054 
LpA  
15.40 
(13.43-16.15) 
15.98 
(15.00-16.93) 
0.129 
Ppg  
14.88  
(13.10-15.83) 
16.20 
(15.80-16.63) 0.018 
Derp1  
14.60 
(13.00-16.60) 
17.00 
(15.30-18.10) 0.050 
GITR 
U  
14.85 
(14.28-17.50) 
16.63 
(16.10-17.90) 
0.059 
LpA  
15.50 
(13.70-16.80) 
16.00 
(15.75-16.85) 
0.156 
Ppg  
15.05 
(12.95-15.95) 
15.88 
(15.50-16.00) 0.035 
Derp1  
15.00 
(12.20-16.20) 
16.25 
(15.15-17.25) 
0.163 
LAG3 
U  
15.93 
(15.93-19.13) 
18.85 
(18.35-19.30) 0.030 
LpA  
16.90 
(15.08-18.48) 
18.20 
(17.20-19.50) 0.030 
Ppg  
16.75 
(14.75-18.20) 
17.73 
(16.80-18.60) 
0.095 
Derp1  
15.60 
(13.70-17.90) 
18.65 
(17.40-20.00) 0.041 
 
Data presented as medians (first/third quartile). *P values calculated with non-parametric Wilcoxon test for 
group comparison of the medians. †Dominant model = wildtype vs heterozygous and SNP homozygous. 
Recessive model =  SNP homozygous vs heterozygous and wildtype.   WT = wildtype, HT = heterozygous, SNP 
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= SNP homozygous, U = unstimulated, LpA = Lipid A, Ppg = Peptidoglycan, Derp1 = Dermatophagoides 
pteronyssinus. ↑ = upregulation or ↓ = downregulation in the presence of the polymorphic allele. Maximum 
number for gene expression analysis:  STAT6 rs324011 n (WT) = 43; n (HT) = 55; n (SNP) =10. Significant 
values are marked in bold. (Casaca et al. 2013). 
 
 
3.1.1.2 Changes in cytokine secretion are associated with STAT6 polymorphisms  
Next cytokine concentrations were assessed in relation to the different STAT6 genotypes. As 
shown in Table IV, following LpA- and Derp1-stimulation, homozygous carries of STAT6 
rs1059513 had increased protein levels of TNF-α (p = 0.038/0.052) and of GM-CSF (p = 
0.023/0.033). 
Furthermore, neonates carrying the minor polymorphic allele of STAT6 rs1059513showed 
increased IFN-γ secretion in unstimulated cells (p = 0.040) (although the expression was 
rather low) and after Ppg-stimulation (p = 0.081).  
Lower TNF-α secretion in carriers of STAT6 rs324011 after Derp1-stimulation (p = 0.044) 
and after LpA-stimulation (trend, p = 0.085) (Table IV) was found. No changes in GM-CSF 
expression were observed. Changes in Th2 cytokines were also detected: trend to lower IL-13 
secretion after Derp1-stimulation (p = 0.063) and IL-5 after innate (LpA, p = 0.061) and 
allergen-stimulation (Derp1, p = 0.059), yet not significant. 
 On the other hand, IFN-γ (Th1) showed an upregulation in homozygous and heterozygous 
carriers of STAT6 rs324011 polymorphism and after stimulation with LpA (p = 0.020), Ppg (p 
= 0.033) and Derp1 (p = 0.004) (Casaca et l. 2013). 
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Table IV. Cytokine secretion in cord blood in relation to STAT6 rs1059513 and rs324011 
polymorphisms.  
 
Cytokine 
pg/ml 
Stimuli WT HT SNP 
P 
value* 
rs1059513 
TNF-α 
U ↑ 
0.57 
(0.01-1.16) 
0.55 
(0.01-1.35) 
0.91 
(0.01-9.13) 
0.870 
LpA ↑ 
943.73 
(357.01-1757.48) 
1398.86 
(423.04-2046.32) 
4308.41 
(2096.94-7875.38) 0.038 
Ppg ↑ 
2254.23 
(1302.73-3422.19) 
2072.61 
(1313.43-3135.92) 
6546.62 
(2720.25-13075.70) 
0.111 
Derp1 ↑ 
1024.73 
(435.67-1896.18) 
1100.52 
(547.41-3060.25) 
7028.02 
(1729.37-13401.76) 0.052 
GM-CSF 
U ↑ 
0.01 
(0.01-0.21) 
0.01 
(0.01-6.36) 
2.78 
(0.01-14.28) 0.041 
LpA ↑ 
2.19 
(0.01-14.64) 
6.42 
(0.01-55.67) 
295.54 
(13.35-301.23) 0.023 
Ppg ↑ 
84.43 
(6.07-364.82) 
9.72 
(0.01-194.80) 
112.70 
(18.04-781.61) 
0.178 
Derp1 ↑ 
13.14 
(0.01-105.23) 
37.24 
(1.42-275.90) 
623.82 
(85.25-649.46) 0.033 
IL-13 
U ↓ 
0.43 
(0.24-0.78) 
0.37 
(0.06-0.84) 
0.01 
(0.01-0.15) 0.045 
LpA ↑ 
4.68 
(1.87-12.34) 
6.23 
2.01-15.25 
7.75 
(7.70-7.92) 
0.591 
Ppg ↑ 
26.80 
(10.48-61.24) 
25.39 
(9.16-53.74) 
27.36 
(18.77-34.65) 
0.720 
Derp1 ↑ 
10.12 
(3.40-19.84) 
10.22 
(3.42-27.26) 
18.00 
(13.42-20.59) 
0.498 
IL-5 
U ↑ ↓ 
0.10 
(0.01-0.17) 
0.10 
(0.01-0.16) 
0.01 
(0.01-0.10) 
0.441 
LpA ↑ 
6.31 
(2.64-17.20) 
8.23 
(3.22-14.60) 
9.47 
(1.49-47.03) 
0.675 
Ppg ↑ 
28.94 
(11.82-67.65) 
25.11 
(5.28-44.41) 
30.87 
(1.79-74.45) 
0.514 
Derp1 ↑ 
10.73 
(4.71-22.59) 
9.29 
(6.29-22.43) 
15.26 
(2.70-106.90) 
0.833 
IFN-γ 
U ↑ 
0.01 
(0.01-1.01) 
0.13 
(0.01-2.49) 
2.53 
(0.01-3.18) 0.040 
LpA ↓ 
43.84 
(6.18-98.95) 
24.99 
(3.72-76.65) 
17.29 
(13.78-45.23) 
0.514 
Ppg ↓ 
49.64 
(15.98-130.31) 
23.80 
(4.96-100.08) 
32.95 
(25.26-61.60) 
0.081 
Derp1 ↓ 
47.41 
(9.71-121.80) 
36.62 
(5.63-118.62) 
30.56 
(13.57-67.71) 
0.737 
rs324011 
TNF-α 
U ↓ 
0.77 
(0.01-1.24) 
0.58 
(0.01-1.15) 
0.11 
0.01-0.97 
0.161 
LpA ↓ 
1124.07 
(530.60-1970.03) 
938.18 
(350.42-1757.48) 
787.74 
(207.11-1502.44) 
0.085 
Ppg ↓ 
2589.49 
(1403.13-3560.77) 
1997.07 
(1345.51-3316.99) 
1670.61 
(1172.47-3144.03) 
0.214 
Derp1 ↓ 
1121.41 
(648.25-2884.49) 
1095.66 
(395.68-1741.80) 
738.75 
(346.33-1538.55) 0.044 
GM-CSF U - 
0.01 
(0.01-2.78) 
0.01 
(0.01-0.16) 
0.01 
(0.01-1.02) 
0.470 
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LpA ↓ 
6.07 
(0.01-25.20) 
1.47 
(0.01-20.12) 
0.78 
(0.01-10.14) 
0.484 
Ppg ↑ 
61.45 
(5.84-219.57) 
106.04 
(3.64-348.92) 
84.94 
(9.26-399.79) 
0.698 
Derp1 ↓ 
34.22 
(0.92-208.03) 
10.48 
(0.01-104.79) 
7.60 
(0.01-49.87) 
0.204 
IL-13 
U ↑ 
0.37 
(0.15-0.74) 
0.47 
(0.27-0.79) 
0.41 
(0.18-0.79) 
0.258 
LpA ↑ ↓ 
4.33 
(2.24-14.72) 
6.03 
(1.93-12.99) 
3.11 
(1.19-7.80) 
0.222 
Ppg ↑↓ 
24.39 
(11.16-60.86) 
28.01 
(10.53-65.84) 
19.16 
(9.32-44.73) 
0.528 
Derp1 ↓ 
10.46 
(5.98-20.59) 
10.50 
(4.09-28.85) 
5.14 
(1.99-12.85) 
0.063 
IL-5 
U ↓ 
0.13 
(0.01-0.19) 
0.02 
(0.01-0.13) 
0.04 
(0.01-0.16) 
0.069 
LpA ↓ 
8.47 
(3.66-21.82) 
6.25 
(2.45-15.35) 
4.69 
(1.24-8.49) 
0.061 
Ppg ↓ 
29.13 
(10.80-72.92) 
32.40 
(10-78-68.69) 
21.62 
(11.82-48.29) 
0.567 
Derp1 ↓ 
10.97 
(6.90-22.59) 
11.00 
(3.96-26.54) 
5.95 
(2.94-12.71) 
0.059 
IFN-γ 
U - 0.01 
(0.01-1.02) 
0.01 
(0.01-1.03) 
0.01 
(0.01-1.02) 
0.765 
LpA ↑ 
20.90 
(3.70-85.07) 
48.82 
(15.19-105.78) 
27.85 
(3.86-51.04) 0.020 
Ppg ↑ 
27.88 
(8.74-117.59) 
58.12 
(19.30-134.00) 
42.51 
(7.14-59.11) 0.033 
Derp1 ↑ 
23.53 
(5.99-119.48) 
72.37 
(21.79-130.23) 
31.87 
(5.88-51.69) 0.004 
 
Data presented as medians (first/third quartile). WT = wildtype, HT = heterozygous, SNP = SNP homozygous. U 
= Unstimulated, LpA = Lipid A, Ppg = Peptidoglycan, Derp1 = Dermatophagoides pteronyssinus. *Kruskal-
Wallis test. Significant results are marked in bold. ↑ = upregulation or ↓ = downregulation in the presence of the 
polymorphic allele. Maximum number for cytokine analysis: STAT6 rs1059513 n (WT) =152; n (HT) = 32; n 
(SNP) = 3 and STAT6 rs324011 n (WT) = 73; n (HT) = 90; n (SNP) = 24.(Casaca et al. 2013). 
 
 
 
 
 
When the genetic models (dominant and recessive) were applied most of the cytokine data 
retained their statistical significance as in the 3 group comparisons, for both STAT6 
polymorphisms (Table V).  
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Table V. Dominant and recessive models comparing results of cyt kine secretion depending 
on STAT6 polymorphisms.   
 
 
 
 
 
 
 
  Dominant†  Model 
  rs1059513 rs324011 
Cytok. 
pg/ml 
Stim. WT HT+SNP 
P * 
value 
WT HT+SNP P * 
value 
TNF-α 
U 
0.57 
(0.01-1.16) 
0.55 
(0.01-1.47) 
0.972 
0.77 
(0.01-1.24) 
0.50 
(0.01-1.15) 
0.238 
LpA 
943.73 
(357.01-
1757.48) 
1555.43 (433.90-
2345.46) 
0.094 
1124.07 
(530.60-
1970.03) 
875.64 
(307.17-1721.07) 
0.056 
Ppg 
2254.23 
(1302.73-
3422.19) 
2112.51 
(1330.50-
3253.58) 
0.975 
2589.49 
(1403.13-
3560.77) 
1958.18 
(1250.78-
3316.99) 
0.101 
Derp
1 
1024.73 
(435.67-
1896.18) 
1291.52 
(688.71-3105.12) 
0.114 
1121.41 
(648.25-
2884.49) 
976.49 
(390.06-1703.11) 0.038 
GM-
CSF 
U 
0.01 
(0.01-0.21) 
0.01 
(0.01-6.61) 0.017 
0.01 
(0.01-2.78) 
0.01 
(0.01-0.26) 
0.545 
LpA 
2.19 
(0.01-14.64) 
8.09 
(0.01-162.20) 0.054 
6.07 
(0.01-25.20) 
0.78 
(0.01-16.90) 
0.243 
Ppg 
84.43 
(6.07-364.82) 
29.03 
(1.76-194.80) 
0.138 
61.45 
(5.84-219.57) 
98.13 
(4.31-391.45) 
0.480 
Derp
1 
13.14 
(0.01-105.23) 
41.53 
(4.25-276.40) 0.055 
34.22 
(0.92-208.03) 
10.28 
(0.01-103.27) 
0.083 
IL-13 
U 
0.43 
(0.24-0.78) 
0.37 
(0.01-0.77) 
0.183 
0.37 
(0.15-0.74) 
0.47 
(0.25-0.79) 
0.175 
LpA 
4.68 
(1.87-12.34) 
7.70 
(2.24-14.72) 
0.348 
4.33 
(2.24-14.72) 
5.21 
(1.61-11.62) 
0.442 
Ppg 
26.80 
(10.48-61.24) 
25.44 
(9.51-50.36) 
0.439 
24.39 
(11.16-60.86) 
27.66 
(10.42-59.34) 
0.714 
Derp
1 
10.12 
(3.40-19.84) 
15.09 
(4.09-24.84) 
0.382 
10.46 
(5.98-20.59) 
10.17 
(3.23-20.92) 
0.488 
IL-5 
U 
0.10 
(0.01-0.17) 
0.10 
(0.01-0.16) 
0.960 
0.13 
(0.01-0.19) 
0.02 
(0.01-0.15) 0.023 
LpA 
6.31 
(2.64-17.20) 
8.24 
(3.05-15.37) 
0.389 
8.47 
(3.66-21.82) 
5.45 
(2.43-14.15) 0.044 
Ppg 
28.94 
(11.82-67.65) 
27.99 
(5.28-44.71) 
0.250 
29.13 
(10.80-72.92) 
27.69 
(11.38-60.34) 
0.655 
Derp
1 
10.73 
(4.71-22.59) 
10.13 
(6.29-22.43) 
0.627 
10.97 
(6.90-22.59) 
9.12 
(3.81-22.43) 
0.080 
IFN-γ 
U 
0.01 
(0.01-1.01) 
0.24 
(0.01-2.53) 0.017 
0.01 
(0.01-1.02) 
0.01 
(0.01-1.03) 
0.466 
LpA 
43.84 
(6.18-98.95) 
22.69 
(3.74-72.90) 
0.253 
20.90 
(3.70-85.07) 
44.23 
(9.24-98.31) 
0.105 
Ppg 
49.64 
(15.98-130.31) 
24.93 
(5.74-61.60) 0.028 
27.88 
(8.74-117.59) 
50.88 
(17.40-123.26) 
0.073 
Derp
1 
47.41 
(9.71-121.80) 
33.59 
(6.89-99.12) 
0.440 
23.53 
(5.99-119.48) 
52.53 
(13.77-118.44) 
0.120 
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Table V. (Continued). 
 
 
 
Data presented as medians (first/third quartile). 
*P values calculated with non-parametric Wilcoxon test for group comparison of the medians. †Dominant model 
= wildtype vs heterozygous and SNP homozygous. Recessive model =  SNP homozygous vs heterozygous and 
wildtype.     STAT6 rs1059513 n (WT) = 152; n (HT) = 32; n (SNP) = 3 and STAT6 rs324011 n (WT) = 73; n 
(HT) = 90; n (SNP) = 24. WT = wildtype, HT = heterozygous, SNP = SNP homozygous. U = unstimulated, LpA 
 Recessive† model 
 rs1059513   rs324011  
Cytok. 
pg/ml 
Stim. WT+HT SNP 
P 
value
*  
WT+HT SNP 
P 
value
*  
TNF-α 
U 
0.55 
(0.01-1.17) 
0.91 
(0.01-9.13) 
0.623 
0.65 
(0.01-1.17) 
0.11 
0.01-0.97 
0.073 
LpA 
974.66 
(369.02-
1857.59) 
4308.41 
(2096.94-
7875.38) 
0.021 
1045.80 
(391.87-
1934.48) 
787.74 
(207.11-1502.44) 
0.097 
Ppg 
2171.48 
(1313.43-
3313.31) 
6546.62 
(2720.25-
13075.70) 
0.045 
2270.20 
(1359.88-
3328.75) 
1670.61 
(1172.47-
3144.03) 
0.275 
Derp1 
1035.23 
(451.42-
1977.79) 
7028.02 
(1729.37-
13401.76) 
0.027 
1103.84 
(495.75-
2223.45) 
738.75 
(346.33-1538.55) 0.052 
GM-
CSF 
U 
0.01 
(0.01-0.87) 
2.78 
(0.01-14.28) 
0.152 
0.01 
(0.01-0.87) 
0.01 
(0.01-1.02) 
0.408 
LpA 
2.62 
(0.01-20.12) 
295.54 
(13.35-301.23) 0.017 
4.03 
(0.01-20.61) 
0.78 
(0.01-10.14) 
0.527 
Ppg 
78.85 
(4.86-338.54) 
112.70 
(18.04-781.61) 
0.506 
78.85 
(4.13-332.10) 
84.94 
(9.26-399.79) 
0.511 
Derp1 
15.81 
(0.01-107.72) 
623.82 
(85.25-649.46) 0.025 
16.68 
(0.01-122.80) 
7.60 
(0.01-49.87) 
0.368 
IL-13 
U 
0.41 
(0.21-0.78) 
0.01 
(0.01-0.15) 0.017 
0.40 
(0.21-0.77) 
0.41 
(0.18-0.79) 
0.639 
LpA 
4.89 
(1.87-13.19) 
7.75 
(7.70-7.92) 
0.524 
5.21 
(1.93-13.29) 
3.11 
(1.19-7.80) 
0.087 
Ppg 
25.71 
(9.95-60.42) 
27.36 
(18.77-34.65) 
0.991 
25.71 
(10.53-62.05) 
19.16 
(9.32-44.73) 
0.365 
Derp1 
10.12 
(3.42-21.83) 
18.00 
(13.42-20.59) 
0.314 
10.48 
(4.30-24.84) 
5.14 
(1.99-12.85) 0.019 
IL-5 
U 
0.10 
(0.01-0.16) 
0.01 
(0.01-0.10) 
0.225 
0.10 
(0.01-0.16) 
0.04 
(0.01-0.16) 
0.748 
LpA 
6.42 
(2.70-15.37) 
9.47 
(1.49-47.03) 
0.679 
7.61 
(2.89-18.15) 
4.69 
(1.24-8.49) 
0.075 
Ppg 
27.69 
(11.78-65.77) 
30.87 
(1.79-74.45) 
0.767 
31.37 
(10.78-71.01) 
21.62 
(11.82-48.29) 
0.292 
Derp1 
10.45 
(4.84-22.51) 
15.26 
(2.70-106.90) 
0.634 
10.99 
(5.14-23.12) 
5.95 
(2.94-12.71) 0.041 
IFN-γ 
U 
0.01 
(0.01-1.103) 
2.53 
(0.01-3.18) 
0.149 
0.01 
(0.01-1.03) 
0.01 
(0.01-1.02) 
0.780 
LpA 
40.13 
(5.74-96.96) 
17.29 
(13.78-45.23) 
0.662 
43.20 
(6.40-101.16) 
27.85 
(3.86-51.04) 
0.092 
Ppg 
45.49 
(12.38-
120.71) 
32.95 
(25.26-61.60) 
0.877 
46.27 
(14.07-127.84) 
42.51 
(7.14-59.11) 
0.209 
Derp1 
47.13 
(7.95-120.33) 
30.56 
(13.57-67.71) 
0.749 
51.00 
(10.60-129.22) 
31.87 
(5.88-51.69) 0.017 
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= Lipid A, Ppg = Peptidoglycan, Derp1 = Dermatophagoides pteronyssinus. ↑ = upregulation or ↓ = 
downregulation in the presence of the polymorphic allele. Significant values are marked in bold.  
(Casaca et al. 2013). 
 
 
 
 
To further understand possible immune regulation dependent on the STAT6 rs324011 
genotype, potential correlations of FOXP3 (Table VI) with changes at protein level of IFN-γ 
(Th1), IL-5, IL-13 (Th2) and TNF-α (pro-inflammatory) secretion were assessed without and 
following stimulation. 
Wildtype and heterozygous carriers showed a moderate positive correlation between FOXP3 
expression and IFN-γ (r = 0.4, p = 0.01; r = 0.3, p = 0.039, respectively) at baseline (media, 
U). On the other hand, the homozygous carriers of the SNP showed a trendwise strong 
negative correlation (r = -0.7, p = 0.11) of FOXP3 and IFN-γ. Regarding correlations with 
Th2 and pro-inflammatory cytokine secretion, significant negative associations between 
FOXP3 expression and IL-5 (r = -0.7, p < 0.0001), IL-13 (r = -0.4, p = 0.006) and TNF-α (r = 
-0.5, p = 0.0017) were found in neonates carrying the wildtype allele of STAT6 rs324011. 
Further negative correlations were observed in heterozygous carriers of STAT6 rs324011, for 
FOXP3 expression and IL-5 (r = -0.4, p = 0.001) and TNF-α (r = -0.4, p=0.0008). The overall 
population showed a comparable pattern which was not observed in the homozygous carriers 
of STAT6 rs324011 Similarly to FOXP3, gene expression of LAG3 was also highly inversely 
correlated with IFN-γ secretion (r = -0.8, p = 0.011, LpA) in homozygous carriers of 
rs324011. Homozygous carriers of the SNP also showed a positive correlation of GITR gene 
expression and TNF-α (r = 0.7, p=0.026) and borderline significant with IL-5 (r = 0.6, p = 
0.073). On the other hand, heterozygous and wildtype carriers showed a significant negative 
correlation of GITR with IL-5 and TNF-α (Casaca et al. 2013). Overall, correlation of FOXP3 
gene expression with Th1 IFN-γ and with Th2 cytokines IL-5 and IL-3 was different i  
homozygous carriers of STAT6 rs324011 and heterozygous/wildtype neonates. 
RESULTS 
 
40 
 
For the second STAT6 SNP, rs1059513, wildtype neonates showed a significa t correlation of 
FOXP3 with IFN-γ (r = 0.4, p = 0.0001), IL-5 (r = -0.5, p < 0.0001), TNF-α (r = -0.5, p ≤ 
0.0001) and almost significant with IL-13 (r = -0.2, p = 0.060, unstimulated). The 
homozygous carriers of STAT6 rs1059513 had a similar pattern of correlation betwe n 
FOXP3 and IL-5 and between FOXP3 and IL-13 (p ≤ 0.05). Gene expression of the other two 
Treg-associated markers, GITR and LAG3 showed an overall pattern of correlation with 
cytokines (protein level) as FOXP3 (mRNA level) (Casaca et al. 2013). In summary wildtype 
and carriers of STAT6 rs1059513 showed similar correlation of Treg-related FOXP3 gene 
expression and Th2 cytokines. 
 
 
 
Table VI. Correlations of FOXP3 gene expression with cytokine secretion in CBMCs 
depending on STAT6 polymorphisms.  
Treg 
marker 
Stimuli Genotype  
IFN-γ 
(pg/ml) 
IL-5 
(pg/ml) 
IL-13 
(pg/ml) 
TNF-α 
(pg/ml) 
 rs1059513 
FOXP3 
(∆Ct) 
U 
WT 
r 
p 
0.4 
0.0001 
-0.5 
< 0.0001 
-0.2 
0.060 
-0.5 
< 0.0001 
n 83 84 84 84 
HT + 
SNP 
r 
p 
-0.1 
0.820 
-0.5 
0.022 
-0.5 
0.054 
-0.3 
0.275 
n 18 18 18 18 
LpA 
WT 
r 
p 
0.1 
0.526 
-0.3 
0.018 
-0.3 
0.011 
-0.1 
0.287 
n 72 70 71 72 
HT + 
SNP 
r 
p 
0.1 
0.858 
0.2 
0.558 
-0.0 
0.979 
0.1 
0.628 
n 13 13 13 13 
Ppg 
WT 
r 
p 
-0.06 
0.591 
0.0 
0.731 
-0.11 
0.365 
-0.2 
0.072 
n 66 65 66 66 
HT + 
SNP 
r 
p 
-0.3 
0.325 
0.2 
0.415 
0.01 
0.957 
-0.2 
0.494 
n 13 13 13 13 
Derp1 
WT 
r 
p 
0.1 
0.611 
-0.3 
0.061 
-0.2 
0.187 
-0.3 
0.075 
n 47 46 46 46 
HT + 
SNP 
r 
p 
0.4 
0.385 
-0.4 
0.319 
-0.5 
0.233 
-0.7 
0.047 
n 8 8 8 8 
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 rs324011 
FOXP3 
(∆Ct) 
U 
WT 
r 
p 
0.4 
0.010 
-0.7 
< 0.0001 
-0.4 
0.006 
-0.5 
0.0017 
n 41 41 41 41 
HT 
r 
p 
0.3 
0.039 
-0.4 
0.001 
-0.18 
0.196 
-0.4 
0.0008 
n 54 55 55 55 
SNP 
r 
p 
-0.7 
0.111 
0.3 
0.538 
-0.4 
0.351 
0.4 
0.346 
n 7 7 7 7 
LpA 
WT 
r 
p 
-0.1 
0.649 
-0.1 
0.524 
-0.3 
0.097 
-0.2 
0.231 
n 36 36 36 36 
HT 
r 
p 
0.3 
0.081 
-0.24 
0.131 
-0.3 
0.047 
0.0 
0.813 
n 43 42 42 43 
SNP 
r 
p 
0.1 
0.969 
-0.0 
0.957 
-0.3 
0.478 
0.0 
0.939 
n 7 6 7 7 
Ppg 
WT 
r 
p 
-0.1 
0.475 
0.3 
0.095 
0.1 
0.471 
-0.0 
0.960 
n 32 32 32 32 
HT 
r 
p 
0.0 
0.924 
-0.1 
0.642 
-0.2 
0.234 
-0.2 
0.231 
n 40 40 40 40 
SNP 
r 
p 
0.14 
0.760 
-0.6 
0.208 
-0.7 
0.071 
-0.3 
0.482 
n 6 6 7 7 
Derp1 
WT 
r 
p 
0.3 
0.162 
-0.3 
0.141 
-0.31 
0.164 
-0.3 
0.164 
n 21 21 21 21 
HT 
r 
p 
0.0 
0.963 
-0.1 
0.585 
-0.0 
0.893 
-0.1 
0.711 
n 30 29 29 29 
SNP 
r 
p 
-0.8 
0.200 
-0.4 
0.600 
-0.4 
0.600 
0.0 
1.000 
n 4 4 4 4 
 
 r = Spearman correlation coefficients. P ≤ 0.01 is significant. WT = wildtype, HT = heterozygous, SNP = SNP 
homozygous. U = Unstimulated, LpA = Lipid A, Ppg = Peptidoglycan, Derp1 = Dermatophagoides 
pteronyssinus. Heterozygotes and minor allele homozygotes of rs1059513 were combined to increase statistical 
power. (Casaca et al. 2013). 
 
 
In summary, STAT6 rs324011 polymorphism was associated with downregulation of Treg- 
associated genes. Furthermore, neonates with this polymorphic allele showed reduced 
production of IFN-γ. On the other hand STAT6 rs1059513 polymorphism was associated with 
increased concentrations of GM-CSF and TNF-α. 
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3.1.2 Modulation of neonatal immune responses by Th1 polymorphisms: TBX21 and 
HLX1 
 
3.1.2.1 Changes in cytokine secretion are associated with TBX21 and HLX1 
polymorphisms 
Neonates carrying TBX21 rs17250932 and HLX1 rs2738751 showed a decrease (or trend) for 
IL-5 (p = 0.03; 0.05) and IL-13 (p = 0.06, 0.05) secretion upon LpA-stimulation. Also carriers 
of HLX1 rs2738751 showed lower IL-13 after Ppg-stimulation compared to wildtype and 
heterozygous. These two polymorphic genotypes (TBX21 rs17250932 and HLX1 rs2738751) 
were also associated with low secretion of TNF-α (Figure 3). 
Investigating the influence of HLX1 SNP rs12141189 showed that homozygous carriers had 
significant (or trend to) higher IL-5 (p = 0.007/0.1), IL-13 (p = 0.1) and GM-CSF (p = 
0.03/0.05) secretion upon LpA and Ppg-stimulation. IFN- γ Th1-associated cytokine  
secretion was downregulated (trend, p = 0.1) in the homozygous carriers (upon D+L-
stimulation) (Figure 4). 
The presence of HLX1 SNP rs3806325 was associated with higher secretion of IL-13 and IL-6 
at baseline (Table VII). No associations were found between TBX21 SNP rs11079788 and 
cytokine modulation, however the SNP carriers presented increased activation of effector T 
cells (CD4+CD25+). 
Application of the recessive model generally led to increased statistical significance of the 
findings (Table VII) (Casaca et al. 2012). 
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Figure 3. Cytokine secretion of wildtype, heterozygous and homozygous SNP carriers of TBX21 rs17250932 
and HLX1 rs2738751. Data were shown in boxplots (first, third quartile, median), the whiskers indicate the 
maximum and minimum values, dots indicate outliers, analyzed by Kruskal-Wallis-test. Values were shown in 
pg/ml.  TBX21 rs17250932 n (WT) = 113, n (HT) = 61, n (SNP) = 10, and HLX1 rs2738751 n (WT) = 135, n 
(HT) = 45, n (SNP) = 4 (Casaca et al. 2012). 
TBX21 rs17250932                                              HLX1 rs2738751 
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Figure 4. Cytokine secretion of wildtype, heterozygous and homozygous SNP carriers of HLX1 rs12141189. 
Data were shown in boxplots (first, third quartile, median), the whiskers indicate the maximum and mini um 
values, dots indicate outliers, analyzed by Kruskal-W llis-test. Values were shown in pg/ml. n (WT) = 104, n 
(HT) = 68, n (SNP) = 12 (Casaca et al. 2012). 
 
HLX1 rs12141189 
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3.1.2.2 Gene expression of Th1 and Th2-related markers is associated with TBX21 and 
HLX1 polymorphisms 
Next, gene expression at mRNA level was assessed to investigate influence of the 
polymorphisms on the transcription of Th1 and Th2-related genes. We investigated: TBX21, 
HLX1, IRF1, GATA3, STAT6 and STAT6e. Table VII shows the gene expression (mRNA) 
related to the findings at protein level. TBX21 rs17250932 was associated with decreased 
STAT6e expression in parallel with lower Th2 and pro-inflammatory cytokines. 
TBX21 rs11079788 polymorphism was associated with higher GATA3, HLX1 and IRF1 at 
baseline in parallel with high activated T cells. 
Also, HLX1 rs3806325 was associated with higher expression of GATA3 and STAT6e upon 
LpA-stimulation, in parallel with increased IL-13 and IL-6 cytokine secretion at baseline 
(Table VII). 
Gene expression of the Th1 transcription factor TBX21 was lower in HLX1 rs12141189 SNP 
carriers upon D+L-stimulation. Of note, these carriers presented decrease IFN-γ production. 
Significant changes at gene levels were not observed in relation to HLX1 rs2738751 SNP 
polymorphism (Casaca et al. 2012). 
In summary, the studied Th1 TBX21 and HLX1 polymorphisms showed an association with 
regulation mainly of Th2 cytokines IL-5 and IL-13 upon innate stimulation with LpA. 
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Table VII. Effects of TBX21 and HLX1 polymorphisms on cytokine secretion, T cells and 
mRNA regulation.  
 
Gene/ 
rs number 
Cytokine 
secretion/ T cell  
regulation 
P 
Overall 
P recessive 
model 
mRNA regulation 
P 
Overall 
TBX21 
rs17250932 
IL-5 (LpA)↓ 
IL-13 (LpA)↓ 
TNF-α (LpA)↓ 
0.03 
0.06 
0.07 
0.03 
0.28 
0.16 
No changes with LpA 
STAT6e (U)↓ 
- 
0.01 
TBX21 
rs11079788 
CD4+CD25+ (U)↑ 0.04 0.23 
GATA3  (U) ↑ 
HLX1  (U) ↑ 
IRF1 (U) ↑ 
0.08 
0.02 
0.01 
HLX1 
rs2738751 
IL-5 (LpA)  ↓ 
IL-13 (LpA) ↓ 
IL-13 (Ppg)↓ 
TNF-α (LpA) ↓ 
0.05 
0.05 
0.08 
0.04 
0.02 
0.02 
0.03 
0.01 
No changes with LpA 
or Ppg 
- 
HLX1 
rs3806325 
IL-13 (U) ↑ 
IL-6 (U) ↑ 
0.005 
0.03 
0.003 
0.05 
GATA3 (LpA) ↑ 
STAT6e (LpA) ↑ 
0.003 
0.007 
HLX1 
rs12141189 
IL-5  LpA ↑ 
IL-13  LpA ↑ 
GM-CSF  LpA ↑ 
IL-5 (Ppg) ↑ 
GM-CSF (Ppg)  ↑ 
IFN- γ (D+L) ↓ 
0.007 
0.1 
0.03 
0.1 
0.05 
0.1 
0.002 
0.04 
0.009 
0.09 
0.02 
0.03 
TBX21 (D+L) ↓ 0.02 
 
LpA=Lipid A; Ppg=Peptidoglycan and U=unstimulated, D+L=Dermatophagoides pteronyssinus 1 and Lipid A; 
↑: expression upregulated; ↓: expression downregulated. P values analyzed by Kruskal-Wallis-test (overall, 3 
categories) or Wilcoxon-test (recessive model, 2 categories).  Genotype comparison includes the comparison of 
the respective genotype groups used for statistical an lysis of mRNA expression; statistics performed by 
generalized Wilcoxon test. Significance (p≤0.05) is marked in bold (Casaca et al. 2012). 
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3.1.3 Association of Th2 STAT6, Th1 TBX21 and HLX1 polymorphisms with early 
disease development 
 
When children turned 3 years, parents completed extensive questionnaires to assess allergic 
and respiratory diseases. Next the influence of Th1/ 2 polymorphisms in relation to clinical 
outcomes was assessed. 
As shown in Table VIII, children that carried the STAT6 rs324011 SNP showed a significant  
lower risk for doctor’s diagnosis of atopic dermatitis (AD) (p = 0.046). AD prevalence was 
20.6 % in the wildtype, 11.5 % in the heterozygous and 4.3 % in the SNP homozygous 
carriers group. Furthermore, wildtype children also showed the highest risk of a doctor’s 
diagnosis of obstructive bronchitis with 19.1 % compared to 11.5 % of heterozygous and 0 % 
of the homozygous. When applying the recessive and dominant models (χ2 test), in relation to 
the clinical outcomes the significance of the results before mentioned remained (not shown). 
No associations were found between STAT6 rs1059513 and respiratory and allergic diseases 
at age 3 years. 
 
Table VIII. Prevalence of clinical outcomes in children in relation to STAT6 rs324011 
genotypes.  
 
Phenotype 
Genotypes % (n/N) 
P value* WT HT SNP 
 Atopic dermatitis 20.6 (13/63) 11.5 (10/87) 4.4 (1/23) 0.046 
Food allergy 1.6 (1/63) 2.3 (2/87) 0.0 (0/23) 0.951 
Symptoms of Food allergy 11.1 (7/63) 10.3 (9/87) 4.4 (1/23) 0.629 
Obstructive bronchitis 19.1 (12/63) 11.5 (10/87) 0 (0/23) 0.048 
 
Data are shown in percentages and number of cases within the respective groups. *Differences between groups 
were calculated with Mantel-Haenszel test. WT = wildtype, HT = heterozygous, SNP = SNP homozygous.  
Atopic dermatitis = Doctor’s diagnosis of AD; Food allergy = Doctor’s diagnosis of food allergy; Symptoms of 
food allergy = parental report of symptoms of food allergy; Obstructive bronchitis = Doctor’s diagnosis of 
asthma ever or repeated obstructive bronchitis. Outcome data assessed within the group of children with 
available genotyping data (Casaca et al. 2013). 
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As for Th1 polymorphisms, TBX21 rs11079788 SNP carriers showed less symptoms of atopic 
dermatitis compared to the heterozygous and wildtype group (19 % vs 23 % vs 36 %, p = 
0.03). No other significant associations were found for the rest of the studied polymorphisms. 
 
3.1.4 Th1 and Th2 polymorphisms and maternal atopy 
 
 
It was shown that the atopic status of the mother can modulate SNP-mediated immune 
responses (Liu, Rädler et al. 2011). Consequently the potential role of maternal atopy on the 
Th2 and Th1 polymorphism-modulated immune responses was aimed to be investigated.  
Stratification of the STAT6 polymorphisms showed similar MAF in neonates from atopic and 
non-atopic mothers, thus no association of the matern l atopy was expected (Table IX). For 
the Th1 polymorphisms, the MAF differed slightly (Table X). Comparison of the influence of 
the maternal status showed no differences on the Th1 polymorphisms immune modulation. 
However stratification by the maternal atopic status lead to very low numbers of homozygous 
carriers.  
 
 
Table IX. Distribution of minor allele frequencies of the STAT6 polymorphisms in neonates 
from atopic and nonatopic mothers. 
Polymorphism Maternal atopy 
WT/HT/SNP 
(n) 
MAF 
STAT6 rs1059513 
No 100/21/1 0.09 
Yes 55/12/2 0.11 
STAT6 rs324011 
No 50/55/17 0.36 
Yes 24/37/8 0.38 
 
*P value calculated with Mantel-Haenszel test. MAF = Minor Allele Frequency. (n) = number of children. WT = 
wildtype, HT = heterozygous, SNP = SNP homozygous (Casaca et al. 2013). 
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Table X. Distribution of minor allele frequencies of the TBX21 and HLX1 polymorphisms in 
neonates from atopic and non-atopic mothers.  
 
Gene/rs number 
Maternal 
atopy 
WT/HT/SNP 
(n) 
MAF 
TBX21 rs17250932 
No 68/46/7 0.25 
Yes 48/18/3 0.17 
TBX21 rs11079788 
No 53/58/10 0.32 
Yes 40/23/6 0.25 
HLX1 rs2738751 
No 88/32/2 0.15 
Yes 50/16/2 0.15 
HLX1 rs3806325 
No 84/36/2 0.16 
Yes 43/23/3 0.21 
HLX1 rs12141189 
No 66/47/8 0.20 
Yes 42/24/4 0.23 
 
*P value calculated with Mantel-Haenszel test. MAF = Minor Allele Frequency. (n) = number of children. WT = 
wildtype, HT = heterozygous, SNP = SNP homozygous (Casaca et al. 2012). 
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3.2 Role of regulatory T cells in the context of farm exposures and allergic 
disease and asthma 
 
The PASTURE (Protection against allergy: study in rural environments) study and the follow-
up study EFRAIM (Mechanisms of Early Protective Exposures on Allergy Development) is a 
large international birth cohort study of children from Austria, Finland, France, Germany and 
Switzerland (von Mutius et al. 2006) designed to investigate the protective factors against the 
development of allergies in early life. The PASTURE/EFRAIM cohort comprises more than 
1000 children.  
Several studies have repeatedly shown that farm environments have a protective effect against 
the development of asthma, atopy and wheeze in childhood (von Ehrenstein et al. 2000; 
Alfvén et al. 2006; Douwes et al. 2008; Riedler et al. 2001; Riedler et al. 2000). This effect 
may start already in utero through exposure to the maternal farm lifestyle (Schaub et al. 
2009). The mechanisms proposed to date include modulation of regulatory T cell number and 
function (Schaub et al. 2009; Douwes et al. 2008).  
Previously it was shown that the neonates from farming mothers had increased Treg cell 
frequency and also higher Treg suppressive capacity (Schaub et al. 2009). Furthermore, it was 
recently shown that this pattern of higher Treg cells persists in farm children of the 
PASTURE/EFRAIM study until the first 4.5 years of life (Lluis, Depner et al, 2013). 
With age, maturation of the immune system continues to develop, also the number of 
environmental exposures continues to accumulate and the clinical phenotypes become rather 
stable. However no information is known about the protective Treg-farm association after the 
early years. Thus, a subgroup of German children from the PASTURE/EFRAIM international 
birth cohort was studied at age of 6 years to investigate this matter.   
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Here, the frequency of regulatory T cells at the agof 6 years in the entire population is 
presented, then Treg cell frequency and quality is shown in relation to farm/farm exposures 
and in relation to clinical outcomes.  Lastly the influence of farm on clinical outcomes was 
studied.  
 
3.2.1 Population characteristics  
 
A total of 143 children, with Treg cell data available were studied. Table XI displays the main 
population characteristics. The percentages of children exposed to specific farm elements 
such as contact to hay, staying in stables, drinking farm milk was higher in the farming 
children group (approximately 70-90% versus 20-25%).  
Parental atopy was higher in the non-farming group and in general also the percentage of 
children sensitized to specific allergens (using 3 IgE concentration cut-offs: class I ≥ 0.35 
IU/ml; class II ≥ 0.7 IU/mL and class III ≥ 3.5 IU/ml.). The asthma prevalence was slightly 
higher on the non-farming group. 
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Table XI. PASTURE/EFRAIM population characteristics at the agof 6 years.  
Parameters  Farming Non-Farming 
  n % n % 
Regular contact to hay No 14 19.72 54 75.00 
 Yes 57 80.28 18 25.00 
Staying in stable No 9 12.68 59 81.94 
 Yes 62 87.32 13 18.06 
Farm milk consumption No 19 26.76 59 81.94 
 Yes 52 73.24 13 18.06 
Parental atopy No 42 59.15 21 29.58 
 Yes 29 40.85 50 70.42 
Maternal atopy No 47 66.20 45 62.50 
 Yes 24 33.80 27 37.50 
Paternal atopy No 56 80.00 34 47.89 
 Yes 14 20.00 37 52.11 
Older siblings 0-1 43 60.56 62 86.11 
 >=2 28 39.44 10 13.89 
Gender Male 44 61.97 37 51.39 
 female 27 38.03 35 48.61 
Smoking during pregnancy No 70 98.59 60 83.33 
 Yes 1 1.41 12 16.67 
Asthma No 56 78.87 53 73.61 
 Yes 15 21.13 19 26.39 
Sensitization      
Inhalant Class I No 40 56.34 39 54.17 
 Yes 31 43.66 33 45.83 
Inhalant Class II No 47 66.20 43 59.72 
 Yes 24 33.80 29 40.28 
Inhalant Class III No 60 84.51 57 79.17 
 Yes 11 15.49 15 20.83 
Food Class I No 40 56.34 45 62.50 
 Yes 31 43.66 27 37.50 
Food Class II No 45 63.38 51 70.83 
 Yes 26 36.62 21 29.17 
Food Class III No 65 91.55 68 94.44 
 Yes 6 8.45 4 5.56 
Seasonal Class I No 31 43.66 33 45.83 
 Yes 40 56.34 39 54.17 
Seasonal Class II No 36 50.70 38 52.78 
 Yes 35 49.30 34 47.22 
Seasonal Class III No 60 84.51 57 79.17 
 Yes 11 15.49 15 20.83 
 
Total number of children n = 143. Class III ≥ 3.5 IU/ ml, Class II  ≥ 0.7 IU/ ml,  Class I ≥ 0.35 IU/ ml specific IgE against 
food, inhalant and seasonal allergens. Contact to hay, st ying in stable and farm milk consumption percentages are related to 
current exposures (at age 6).
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3.2.2 Regulatory T cell frequency in 6 year old children  
 
To evaluate the Treg cell frequencies, regulatory T cells were defined by the expression of 
CD4, high levels of CD25 (the 20 % top cells) and the intracellular expression of FOXP3, the 
Treg specific transcription factor and master regulator. The number of cells was assessed by 
flow cytometry (Figure 5) and the percentages were calculated in relation to the lymphocyte 
population. The median percentages of Treg cells in the total population were: 0.12 (Q1 = 
0.07; Q3 = 0.23) in media, 0.34 (Q1 = 0.19; Q3 = 0.67) in PI and 0.13 (Q1 = 0.06; Q3 = 0.21) 
in Lps.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Representative flow cytometry plots of Treg cell makers. Treg cells were identified by CD4, high 
levels of CD25 (upper top 20 % cells) and FOXP3.  
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3.2.3 Current farm exposures and Treg cell frequency at age 6 years 
 
In the same study population, it has been demonstrated that regulatory T cells are increased in 
farming children, particularly following farm milk consumption at age 4.5 years (Lluis, 
Depner et al. 2013). In this study, at age 6 years, stratification into 2 groups of farming and 
non-farming children showed that the farming status i self was not significantly associated 
with the frequency of Treg cells at the age of 6 years (in all 3 stimulation conditions) (Table 
XII). Next, specific farm-associated exposures such as staying in stable, regular contact to hay 
and farm milk consumption in the last 12 months (from the 6 year questionnaire) were 
examined in relation to Treg cell numbers.  
Children who spent time in the stable showed a higher percentage of Treg cells at baseline, 
0.16 % (p = 0.02) than children that did not have contact to the stables (0.10 %). As shown in 
Table XII, assessing children who had regular contact to hay and drank farm milk at the age 
of 6 year (consumption in the last 12 months from the 6 year questionnaire) showed a trend 
for higher Treg cells at baseline and lower Treg cells upon Lps-stimulation (not significant). 
Table XII. Association of farm and current farm exposures with Treg cells at age of 6 years.  
Parameters 
Tregs 
M 
P 
Tregs 
PI 
P 
Tregs 
Lps 
P 
Farm 
No 0.11 (0.05-0.21) 
0.29 
0.44 (0.20-0.70) 
0.11 
0.13 (0.08-0.23) 
0.21 
Yes 0.15 (0.07-0.26) 0.29 (0.17-0.61) 0.13 (0.05-0.20) 
Farm milk 
No 0.11 (0.04-0.22) 
0.11 
0.34 (0.19-0.67) 
0.95 
0.13 (0.08-0.26) 
0.10 
Yes 0.15 (0.08-0.26) 0.33 (0.19-0.65) 0.12 (0.05-0.19) 
Staying in 
stable 
No 0.10 (0.04-0.21) 
0.02 
0.34 (0.19-0.63) 
0.41 
0.12 (0.07-0.22) 
0.92 
Yes 0.16 (0.08-0.27) 0.34 (0.23-0.73) 0.13 (0.06-0.20) 
Regular 
contact to hay 
No 0.11 (0.04-0.21) 
0.08 
0.32 (0.19-0.67) 
0.92 
0.13 (0.08-0.26) 
0.13 
Yes 0.15 (0.08-0.27) 0.36 (0.19-0.68) 0.12 (0.06-0.19) 
M = Media/baseline, PI = PMA/ionomycin, Lps = Lipopolysaccharide, 1Q and 3Q. Wilcoxon test. Significant p 
values are marked in bold (p ≤ 0.05). 
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3.2.4 Farm milk consumption during childhood modulates regulatory T cells at age 6 
years  
 
After assessing current exposures (age 6 years) on Treg cells early exposures during 
childhood were assessed to study whether they influe ced Treg cells at age 6 years. Shaping 
of the immune system during pregnancy and early in ife seems to play a big role on immune 
modulation and disease development. Farm milk consumption has been shown to be one of 
the most important specific farm exposures related to isease protection (Loss et al. 2011; 
Waser et al. 2006). Drinking farm milk at early ages, 1 or 1.5 years was associated with 
higher Treg cells at baseline at age 6 years (Figure 6). On the other hand, drinking farm milk 
at age 4 or 5 was significantly associated with lower Treg cells at age 6 years after Lps-
stimulation. The children in each age category were defined by answering “yes” or “no” 
drinking farm milk at that time point, thus children might oscilate overtime between groups.  
Contact to hay or to stable during childhood was not significantly associated with changes in 
Treg cells at the age of 6 years.  
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Figure 6. Association of Treg cell percentages at age 6 years with farm milk consumption from pregnancy until 
age of 6 years at Media (baseline) and upon Lps. Media: Number of children at the timepoints - Preg: FM=60 
NFM=67. 1y:FM=45 NFM=82. 1.5y: FM=52 NFM=73. 2y: FM=60 NFM=67. 3y: FM=59 NFM=67. 4y:FM=59 
NFM=68. 5y: FM= 62 NFM=63. 6y: FM=55 NFM=72. Lps: Preg: FM=64 NFM=69. 1y:FM=47 NFM=86. 1.5y: 
FM=53 NFM=78. 2y: FM=60 NFM=73. 3y: FM=61 NFM=71. 4y:FM=62 NFM=70. 5y: FM=67 NFM=64. 6y: 
FM=60 NFM=73. N at the different timepoints. * p ≤ 0.05. # p ≤ 0.01.  
 
 
 
 
Farm milk comsumption 
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3.2.5 Regulatory T cells and suppression of effector T cell division and cytokine 
production in 6 year old children 
 
In addition to the frequency of regulatory T cells we further investigated the ability of Treg 
cells to suppress cell division of autologous effector T cells following activation with PHA 
(Figure 7) in a subgroup was selected from the German PASTURE/EFRAIM population. 
A subsample of the PASTURE/EFRAIM study population was selected. Antigen-presenting 
cells (CD3-), effector T cells (CD4+CD25-) and Treg cells (CD4+CD25+) were separated and 
incubated at different ratios.  
 
Figure 7. Representative plots. Treg suppression, measured by decrease of CFSE staining during division of 
effector T cells. Left plot shows division of PHA-stimulated effector T cells without addition of Treg cells. 
Middle and right plots show the reduction of effector T cell division (P4) with addition of Treg cells in different 
ratios (1:0.5 and 1:0.25, respectively). 
 
Treg suppressive capacity was evaluated by taking the baseline of effector T cell division with 
PHA into account and is represented by the formula: 
 
 
 
In the total group if children the median of effector T cell division in response to PHA-
stimulation was of 23.75 %. As shown in Table XIII, the addition of Treg cells led to an 
overall decrease of effector T cell division. When Treg cells were added to the culture, 
No Tregs 1:0.5 Teff:Treg ratio 1:0.25 Teff:Treg ratio 
CFSE 
CFSE CFSE 
(Effect cell division without Tregs - Effect cell division with Tregs / Effect cell division without Tregs) x 100 
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effector T cells divided at a lower rate: 6.2 % (at the ratio of Effect/Treg 1:0.5) and 5.35 % (at 
the ratio of Effect/Treg 1:0.25).  
The different ratios of Treg cells (adding 1x104cells or 500 Treg cells to a total of 2000 of 
effector T cells) led to similar results in regards to effector T cell division.   
 
Table XIII. Effector T cell division and Treg suppressive capacity in 6 year old EFRAIM 
children. 
 
 
CD4+CD25- effector T cells (2x104 cells/well) labeled with CFSE, cultured with irradi ted CD3- cells 
(4x104cells/well), and stimulated with PHA (0.8 μg/mL), with CD4+CD25+ Treg cells (1x105, 5x104cells/well, 
ratio 1:0.5 and 1:0.25, respectively). After 72 hours of culture, the percentage of newly divided CD4+CD25- 
effector cells was measured by flow cytometry. 1Q = 1st Quartile; 3Q = 3rd Quartile.  
 
 
 
To further understand the underlying mechanisms of uppression the culture supernatants 
were collected and several cytokines were measured including IL-1β, IL-2, IL-5, IL-9, IL-10, 
IL-13 and IFN-γ (Table XIV) in cultures without Treg cells or with (at 1:0.5 ratio Effect/Treg 
cells). The Th2-associated cytokines IL-5 and IL-13 were strongly decreased when Treg cells 
were in culture. Changes in IL-10 secretion were rather mild, from 2.93 to 2.32 pg/ml. The 
Th1-associated cytokines IL-2 and IFN-γ were also strongly suppressed with Tregs. 
Furthermore, IL-9 was also limited by the Treg cells. No clear downregulation of the pro-
inflammatory IL-1β was observed. 
Effector T cell:Treg cell  
 Effector T cell division 
n min 1Q Median (%) 3Q max 
1:0  20 6.8 12.68 23.75 35.92 50.9 
1:0.5 18 1.4 5.45 6.20 9.65 26.9 
1:0.25 16 1.8 4.8 5.35 8.65 38.1 
  Suppressive Capacity 
1:0.5 18 10.16 51.82 63.74 78.85 94.55 
1:0.25 16 0.78 41.51 64.89 77.86 93 
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Table XIV. Cytokine concentrations with and without Treg cells.  
 
 
 
 
 
Supernatants were collected after 72 hours of culture. Cytokines were measured by Luminex Technology. 
Results are expressed in medians (pg/ml) and 1Q = 1st Quartile and 3Q = 3rd Quartile. 
 
 
3.2.6 IL-2 is significantly modulated in non-farming children 
 
Effector T cell division and cytokine secretion can be inhibited by Treg cells by different 
suppressive mechanisms. To understand whether there were qualitative differences regarding 
suppressive capacity, Treg suppression assays were conducted. Farming and non-farming 
children did not show significantly different suppressive capacity in vitro. Also, consumption 
of farm milk did not influence effector T cell suppression at age 6 years. Besides, Treg cell 
suppressive capacity, cytokines from the cell cultures were also assessed. Cytokines were 
measured with and without Treg cells in the culture. 
Non-farming children showed a significant decrease in IL-2 concentration in co-culture with 
Treg cells; this was not observed in farming children (Figure 8). 
No other changes regarding IL-1β, IL-5, IL-13, IL-10, IL-9 or IFN-γ were observed 
depending on the farm status of the child. 
 
 
 
Cytokine Median (1Q-3Q) pg/ml 
 No Tregs With Treg (1:0.5) 
IL-1 β  23.7 (16.02 - 29.19 ) 21.36 (13.32 - 44.34) 
IL-2 44.68 (16.66 – 73.31) 26.3 (7.88 - 65.29) 
IL-5 4.92 (1.13 - 12.15) 1.42 (0.4 - 6.49) 
IL-9 2.36 (1.32 - 4.85) 1.5 (0.02 - 2.7) 
IL-10 2.93 (1.09 - 3.57) 2.32 (0.39 - 3.27) 
IL-13 68.74 (37.44 - 148.5) 6.15 (0.74 - 28.39) 
IFN-γ 124.4 (66.87 - 280.8) 40.66 (0.02 - 58.5) 
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Figure 8. Concentration of IL-2 (pg/ml). NF = Non farming children; F = Farming children. NF = 10; F = 7.  
 
 
 
3.2.7 Association of regulatory T cell frequency at age 6 years with sensitization and the 
asthmatic status 
 
Impairment of Treg cells has been shown repeatedly to be associated with allergic diseases 
(Smith et al. 2008; Hinz et al. 2012), thus the association of Treg cells at the ag  of 6 and 
sensitization to inhalant and seasonal allergens wa investigated. No associations between 
Treg cell numbers, in none of the stimulation conditions, and sensitization in 6 year old 
children were found (Table XV). 
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Table XV. Treg cells in sensitized and non-sensitized 6 year old children. 
 
 
Outcomes  Treg M P Treg PI P Treg Lps P 
Inhalant IgE 
Class I 
No 0.12 (0.07-0.21) 
0.99 
0.35 (0.19-0.67) 
0.83 
0.13 (0.06-0.21) 
0.94 
Yes 0.13 (0.05-0.24) 0.32 (0.19-0.67) 0.13 (0.06-0.22) 
Inhalant IgE 
Class II 
No 0.12 (0.07-0.20) 
0.67 
0.33 (0.19-0.65) 
0.73 
0.12 (0.06-0.21) 
0.73 
Yes 0.16 (0.05-0.26) 0.41 (0.19-0.74) 0.13 (0.07-0.24) 
Inhalant IgE 
Class III 
No 0.12 (0.07-0.21) 
0.65 
0.33 (0.19-0.66) 
0.54 
0.12 (0.07-0.20) 
0.41 
Yes 0.18 (0.05-0.25) 0.45 (0.23-0.74) 0.14 (0.06-0.30) 
Seasonal IgE 
Class I 
No 0.12 (0.07-0.21) 
0.55 
0.34 (0.19-0.67) 
0.90 
0.12 (0.06-0.20) 
0.46 
Yes 0.16 (0.06-0.25) 0.34 (0.19-0.70) 0.13 (0.07-0.26) 
Seasonal IgE 
Class II 
No 0.12 (0.07-0.20) 
0.53 
0.34 (0.19-0.66) 
0.94 
0.12 (0.06-0.20) 
0.45 
Yes 0.18 (0.05-0.25) 0.37 (0.19-0.70) 0.13 (0.06-0.27) 
Seasonal IgE 
Class III 
No 0.12 (0.07-0.22) 
0.76 
0.34 (0.19-0.67) 
0.75 
0.13 (0.07-0.21) 
0.48 
Yes 0.21 (0.04-0.25) 0.37 (0.19-0.76) 0.15 (0.06-0.32) 
 
Values are shown as medians (percentages of Treg cells in relation to the lymphocyte gate) and 1st and 3rd 
quartiles. Class I ≥ 0.35 IU/ml; Class II ≥ 0.7 IU/ml; Class III ≥ 3.5IU/ml. 
 
When children with current asthma were investigated, hese had significantly higher Treg 
cells upon Lps-stimulation (0.26 vs 0.12 %, p = 0.02) in comparison to children without 
current asthma. This same pattern of higher Treg cells in children with current asthma was 
observed at baseline and after PI-activation, althoug  not statistically significant (M, 0.12 vs
0.24 %, p = 0.27 and PI, 0.34 vs 0.50 %, p = 0.84). 
 
3.2.8 In vitro modulation of IL-2 and IFN-γ depending on the asthmatic status 
 
The suppressive capacity of Treg cells on effector T cells from asthmatic and non-asthmatic 
children did not show statistical differences. However there was an IL-2 and IFN-γ 
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modulation in response to PHA and Treg co-culture, d pending on the asthmatic status 
(Figure 9). 
Non-asthmatics showed a significant consumption of IL-2 in the presence of Treg cells in 
parallel to decreased IFN-γ (p = 0.002 and p ≤ 0.000, respectively). This was not observed in 
the asthmatic group. 
Also, asthmatic children produced significantly more IFN-γ when autologous Treg cells 
where added into the culture compared to non-asthmatics (in response to PHA, p = 0.018). 
APCs and effector T cells in culture (without Tregs) produced higher IFN-γ in the asthmatic 
group (Figure 9). 
 
 
Figure 9. IL-2 and IFN-γ concentrations (pg/ml) in asthmatics and non-asthma ics at the age of 6 years. A) IL-2 
secretion in response to PHA-stimulation, Antigen presenting cells, CD3+ and effector T cells, CD4+CD25- in 
culture. B) IFN-γ secretion in response to PHA-stimulation, Antigen presenting cells, CD3+, effector T cells, 
CD4+CD25- and Treg cells CD4+CD25+ in culture. 
 
 
3.2.9 Farm exposures and clinical outcomes 
 
Next, the influence of current exposures on the asthma ic current status (doctor diagnosis of 
asthma ever and any wheeze episodes in the last year) at the age 6 years was investigated. 
Contact to stable and drinking farm milk at age 6 was associated with lower current asthma 
prevalence (10.84 % vs 2.22 %, p = 0.02; 9.68 % vs 2.5 %, p = 0.054, respectively). 
Investigating how exposures affect the prevalence of asthma (a life time prevalence of a 
doctor’s diagnosis of asthma ever and/or a repeated diagnosis of obstructive bronchitis and/or 
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children which are intermediate, late onset and persistent wheezers after the first 6 years 
and/or children with wheeze without a cold and sympto s between wheeze from age 18 
months to age 6 years) during childhood overall showed that contact to stable, to hay and 
drinking farm milk, generally at ages of 4, 5 and 6 years, was associated with a lower 
prevalence of asthma (Table XVI). No association of the farm status itself with asthma 
prevalence was found.  
 
Table XVI. Farm exposures during and association with the prevalence of asthma. 
 Asthma prevalence % (n/N) 
 Farm milk Staying in stable Contact to hay 
 No Yes No Yes No Yes 
pg 29.03 (27/93) 24.42 (21/86) 31.51 (23/73) 19.59 (19/97) 28.28 (28/99) 18.57 (13/70) 
p 0.48 0.075 0.147 
1y 29.91 (35/117) 20.97 (13/62) 28.72 (27/94) 22.89 (19/83) 27.56 (43/156) 21.74 (5/23) 
p 0.199 0.377 0.556 
1.5y 29.25 (31/106) 23.94 (17/71) 32.91 (26/79) 21.88 (21/96) 29.13 (37/127) 22.00 (11/50) 
p 0.437 0.101 0.337 
2y 29.90 (29/97) 23.17 (19/82) 34.94 (29/83) 20.00 (19/95) 29.82 (34/114) 21.54 (14/65) 
p 0.312 0.025 0.229 
3y 35.05 (34/97) 17.28 (14/81) 34.21 (26/76) 21.57 (22/10 ) 31.78 (34/107) 19.72 (14/71) 
p 0.008 0.060 0.076 
4y 34.41 (32/93) 17.65 (15/85) 35.06 (27/77) 19.80 (20/101) 32.97 (30/91) 19.54 (17/87) 
p 0.011 0.022 0.042 
5y 37.21 (32/86) 16.67 (15/90) 37.65 (31/83) 17.20 (16/93) 31.91 (30/94) 20.73 (17/82) 
p 0.002 0.003 0.094 
6y 32.26 (30/93) 18.75 (15/80) 36.14 (30/83) 16.67 (15/90) 32.95 (29/88) 18.82 (16/85) 
p 0.044 0.004 0.034 
 
Results are shown in median percentages and total numbers. Pg = pregnancy, y = year(s). Significant results are 
marked in bold. 
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4. Discussion 
 
Allergic diseases have reached epidemic proportions n the last years. There is the crucial 
necessity to understand the underlying mechanisms to, in the long run, develop prevention 
strategies and effective therapies. The complexity of these diseases relies on an intricate 
interplay between genetics and environmental exposures, which seems to shape the immune 
system at a very young age, a critical time window f r the development of allergic diseases. 
In this study both genetic and environmental exposures associated with the development of 
allergic diseases were investigated. First, the impact of genetic variants within two crucial cell 
players, Th1 and Th2 cells, on immune modulation early in life (at birth) and their influence 
on the development of allergic diseases during the first 3 years of life was investigated. 
Second, the role of regulatory T cells within the “allergy-protective” farm environment and 
their association with allergic diseases including asthma was examined in older children (6 
years old).  
Several studies have shown that polymorphisms in the STAT6 gene, a Th2 transcription factor, 
were associated with the IgE levels in adults and children (Schedel et al. 2004; Duetsch et al. 
2002; Weidinger et al, 2004; Weidinger et al. 2008). Furthermore STAT6 represents one of 
the candidate genes associated with asthma developmnt (Duetsch et al. 2002). Up to date, no 
studies have been conducted to investigate whether genetic changes in STAT6 can shape the 
immune system at birth and associated with disease dev lopment within the first 3 years of 
life. 
In this study the influence of STAT6 polymorphisms on the modulation of immune responses 
at birth was assessed. 
The STAT6 rs324011 polymorphism was associated with lower gene xpression of Treg-
related markers, FOXP3, LAG3 and GITR in cord blood.  Both STAT6 polymorphisms, 
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rs324011 and rs1059513 were associated with changes i  cytokine patterns, however not with 
mRNA expression of Th1, Th2, Th9, Th17 or Th22-related genes (Casaca et al. 2013).  
Carriers of STAT6 rs324011 produced higher amounts of IFN-γ and lower TNF-α. These 
carriers had lower probability to develop atopic dermatitis and obstructive bronchitis during 
the first 3 years of life. On the other hand, neonates carrying the STAT6 rs1059513 SNP 
presented increased TNF-α and GM-CSF but no associations were observed with disease 
development at the age of 3 years (Casaca et al. 2013). 
In this study decreased of LAG3 upon Derp1 and FOXP3, GITR and LAG3 in different 
conditions using the recessive model were found in STAT6 rs324011 neonate carriers. The 
consistent decrease of Treg-related genes is in accordance with studies that have shown that 
STAT6 plays a role in the modulation of Treg cells (Milkova et al. 2009). Nonetheless, the 
exact mechanism is unknown and further studies are required. It could however be speculated 
that this finding might be related to changes in the NF-κB pathway. The STAT6 rs324011 
polymorphism creates a binding site for NF-κB T-allele specific in the STAT6 gene which is 
not present in the wildtype (Schedel et al. 2009). Studies have shown that blocking NF-κB 
pathway inhibited upregulation of FOXP3 expression (Milkova et al. 2009). Thus, it is 
possible that in the polymorphic allele carriers more NF-κB molecules will be bound to the 
specific binding site created by the rs324011, dimin shing the availability of NF-κB which is 
required in the Treg-pathways. Another possible mechanism to explain the downregulation of 
Treg-related genes could involve direct binding of STAT6 to the FOXP3 gene and subsequent 
lower FOXP3 promoter-activation (Takaki et al. 2008). This is plausible as STAT6 rs324011 
was shown to increase STAT6 expression (Schedel t al. 2009). Of note, using the recessive 
model not only LAG3 was downregulated but also FOXP3 (Ppg/Derp1) and GITR (Ppg). 
At protein level, Th1, Th2 and pro-inflammatory cytokine secretion was altered depending on 
the STAT6 genotypes. This is in accordance with our previous reports showing cytokine 
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modulation already at birth depending on genetic variants located in allergy-associated genes 
(Casaca et al. 2012; Liu, Raedler et al. 2011; Lluis et al. 2011). 
In this study the carriers of STAT6 rs324011 not only had lower Treg-associated gene 
expression but also lower levels of TNF-α and skewed IFN-γ increased response. Taken 
altogether, these patterns of neonatal immune responses may be suggestive for an atopy 
protective phenotype. 
Analysis of the relation between Treg modulation and cytokine secretion showed that 
homozygous carriers of the STAT6 rs324011 had a characteristic pattern of correlation not 
observed in the heterozygous and wildtype neonates: they presented a high negative 
correlation of Treg markers with IFN-γ (statistical trend). In regards to the relation of Treg 
with Th2 and pro-inflammatory cytokines, the homozygous carriers of STAT6 rs324011 
showed a positive correlation of FOXP3 expression with IL-5 and TNF-α. On the other hand, 
heterozygous and wildtype showed a negative correlation. These findings may reflect a 
potential combined regulation of Treg cells and the cytokine profile in cord blood, associated 
with the presence of both polymorphic alleles (rs324011) in the STAT6 gene (Casaca et al. 
2013). These patterns of correlation of the FOXP3 findings were not observed in relation to 
the second STAT6 SNP, rs1059513, indicating potential different modulation mechanisms 
than for STAT6 rs324011.   
In regards to the development of atopic diseases in relation to genetic changes in Th2 
transcription factor, it was shown that children carrying STAT6 rs324011 had a lower 
propensity to develop atopic dermatitis and obstructive bronchitis.  
STAT6 polymorphisms have been associated with food allergy (and with food sensitization 
(Amoli et al. 2002; Hancock et al. 2012) however there was no association with diagnosis f 
food allergy in the present study.  The missing effects may potentially be related to lack of 
power as only 3 children had a doctor diagnosis of fo d allergy, for this reason, it would be of 
great value to investigate the role of STAT6 polymorphisms in a high-risk cohort. 
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Previous studies have shown that decreased Treg cell numbers at birth were associated with 
increased risk of developing egg allergy in early childhood (Smith et al. 2008; Hinz et al. 
2012), and that STAT6 rs324011 polymorphism was associated with increased IgE both in 
children and adults (Schedel et al. 2004, Duetsch et al. 2002; Weidinger et al, 2004; Smith et 
al. 2008). However, in the present study children with this polymorphism (also with 
decreased gene expression of Treg-genes at birth) had a lower association with atopic 
dermatitis and obstructive bronchitis. 
The apparent discrepancy between our results and previous findings (Schedel et al. 2004, 
Duetsch et al. 2002; Weidinger et al, 2004; Smith et al. 2008) may be related to the fact that 
1) disease development was assessed in the present study while the other studies investigated 
IgE levels (Schedel et al. 2004, Duetsch et al. 2002); 2) different stages of immune 
maturation, during the first 3 years of life (our study) versus adult (Duetsch et al. 2002) and 9-
11 year old children (Schedel t al. 2004) and 3) differences in Treg assessment (Smith et al. 
2008). In our study, despite having lower Treg-related gene expression these neonates had a 
robust Th1 response with high secretion of IFN-γ which might be associated with the 
observed lower risk of developing atopic dermatitis and obstructive bronchitis. In agreement 
with these findings, other studies have shown that decreased IFN-γ levels at birth were 
associated with increased risk for atopic diseases nd wheeze (Herberth et al. 2010; Guerra et 
al. 2004). In the present study no associations were found for the other STAT6 polymorphism 
rs1059513 and the development of atopic dermatitis, food allergy and obstructive bronchitis 
(Casaca et al. 2013). 
In addition to study the role of Th2-related polymorphisms early in life, important Th1 SNPs 
were also examined. Polymorphisms in the crucial Th1 transcription factors TBX21 and 
HLX1, showed altered cord blood cytokine patterns depending of the genotypes. IL-5 and IL-
13, both Th2 cytokines, were up- or downregulated dpending on the HLX1 and TBX21 
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polymorphims after innate stimulation. Furthermore, g ne expression of Th1 and Th2-related 
genes partially correlated with the cytokine patterns (Casaca et al. 2012). 
Genetic variants in the TBX21 gene were previously shown to be associated with as ma 
(Chung et al. 2003; Munthe-Kaas et al. 2008; Akahoshi et al. 2005), confirming the relevance 
of the Th1/Th2 balance on Th2-related allergic diseases.  
Previous experiments have shown that TBX21 rs17250932 leads to increased promoter 
activity of the TBX21 gene (Suttner et al. 2009). This may potentially explain why the carriers 
of TBX21 rs17250932 showed lower IL-5 and a trend for lower IL-13, as TBX21 suppresses 
Th2 responses. Using retroviral gene transduction, Szabo and colleagues showed that 
overexpression of TBX21 in Th2 cells decreased IL-4 and IL-5 production (Szabo et al. 2000). 
Another study showed that TBX21 could also suppress the expression of IL-13 and its 
promoter activity (Suzuki et al. 2008). Consistent with those studies, TBX21 knockout mice 
had high production of Th2 cytokines (IL-4, IL-5, IL-13) (Lakos et al. 2006). Furthermore, 
these carriers of TBX21 rs17250932 presented lower expression of STAT6e (Th2), an isoform 
which is a splicing variant that includes intron 17 and intron 18 (Schedel t al. 2009).  
In the present study no changes in the cytokine responses were observed depending on TBX21 
rs11079788, however significant increased frequency of activated T cells and accordingly 
higher expression of Th1 and Th2 genes (GATA3, HLX1, IRF1) were found.  
Similarly to TBX21 polymorphism rs17250932, carriers of HLX1 rs2738751 showed 
decreased IL-5, IL-13 and TNF-α representative of Th2 and pro-inflammatory responses. 
An impaired Th1 response, characterized by lower IFN-γ secretion, was associated with the 
presence of HLX1 rs12141189 SNP. Also at mRNA level, the homozygous neonate carriers 
had decreased TBX21 expression. Since HLX1 can be induced by TBX21 (Mullen et al. 2002), 
the lower expression of TBX21 observed in our study could potentially lead to a 
downregulation of HLX1. This polymorphism was also associated with a skewed Th2 
response (higher IL-5, IL-13). Previously HLX1 had been associated with an asthma-
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protective effect observed in school-age children (Suttner et al. 2009). At a first glance these 
observations in the immune responses in neonates seem to be in contrast with an “asthma 
protective phenotype” as a diminished Th1 and exacerb t d Th2 responses were observed. 
However direct comparisons cannot be done as immune maturation and environmental 
exposures during childhood need to be taken into account. Also, a possible feedback 
mechanism of subsequent reduction of Th2 is possible. 
Similarly, HLX1 rs3806325 was associated with increased GATA3 and STAT6 gene 
expression upon innate stimuli, which may indicate  Th2-biased response. In parallel, 
neonates carrying this SNP had increased levels of IL-3 and IL-6. This SNP was previously 
associated with a higher risk of asthma development in school-age children (Suttner t al. 
2009). Of note, it has been demonstrated that this genetic variant has functional relevance and 
that it leads to higher expression of the HLX1 gene by altering transcription factor binding of 
the HLX1 promoter (Suttner et al. 2009). 
The application of the recessive model, which compares homozygous SNP carriers versus 
heterozygous and wildtype, showed more significant differences, suggesting that the effect is 
stronger when carrying both polymorphic alleles. Taken together, it is important to note that 
different factors account for the development of allergic diseases and changes in the immune 
system due to maturation and specific exposures must be considered (Casaca et al. 2012). 
The majority of the changes depending on TBX21 and HLX1 were upon innate stimulation 
(mainly LpA), thus the effects may be related to TLR4 pathway stimulation. Functional 
studies are necessary to better understand the mechanisms involved.  
Regarding the polymorphisms within the Th1 pathway only one TBX21 SNP rs11079788 was 
associated with less symptoms of atopic dermatitis.  
Thus, it is necessary to further investigate these findings in larger cohorts in order to better 
understand the impact of these genetic variations in the development of allergic diseases in 
childhood. Nonetheless, more information will be obtained from our cohort during the follow-
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up until the age of 6 years. This information will be critical since the allergic phenotypes are 
still evolving during the first years of life. Furthermore, lung function will be available to 
objectively assess asthma including airway obstruction at the age of 6 years. 
It was shown in previous studies that the maternal atopic status can affect the impact of the 
polymorphisms on immune regulation (Liu, Raedler et al. 2011). In the present study, 
additional modulation by the maternal atopic status was not found in relation to the Th1 
polymorphisms. However stratification of the data led to very small groups for some of the 
polymorphisms, which might constitute a limitation. I  relation to Th2 polymorphisms, the 
small number of STAT6 rs1059513 carriers did not allow stratification by the maternal status. 
Nevertheless the MAF was similar (for both for STAT6 rs1059513 and rs324011) in the 
neonates from atopic and non atopic mothers, thus no differences were expected. 
Overall, a few limitations of this study need to be considered. The cytokine secretion was 
measured in the supernatant of PBMCs bulk culture not being possible to identify the specific 
cell origin. Due to low cell availability, Treg cell numbers were only measured in little 
number of children, thus no being feasible to stratify by genotypes and properly analyse it. 
However in this study, this would have been valuable together with Treg-related gene 
expression in relation to the genotypes. In some analyses the statistical power might have 
been limited to the low frequency of polymorphisms. This could partly explain missing 
effects and stresses the need to replicate the study in larger high-risk cohorts as previously 
mentioned.  
Multiple testing is also an important issue, particularly regarding the polymorphisms and birth 
immune outcomes. However adjustment for multiple testing would have not been valuable in 
the present analysis as the immunological parameters w e highly correlated, and expression 
of Treg gene markers (FOXP3, GITR and LAG3 with each other) and pro-inflammatory and 
Th2 cytokines were correlated. 
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The strength of this work is a comprehensive study of how the Th1/Th2 polymorphisms are 
associated with neonatal immune responses, assessed at protein and mRNA levels under 
several stimulation conditions, and further influenc  the development of allergic diseases at a 
very young age. Furthermore, continuation of the follow-up of this 200 children will provide 
further information on whether the polymorphisms can further shape disease development in 
childhood.  
While in the first part of the thesis the role of genetic variants in immune modulation and 
allergy development early in life was presented, in the second part the relevance of 
environmental exposures such as the allergy-protective farming environment was 
investigated. The aim was to investigate whether farm itself and specific farm exposures 
modulate regulatory T cells at age 6 years and its relation to development of allergic diseases 
and asthma.  
The German children assessed in this work belonged to the large international birth cohort 
PASTURE/EFRAIM study, which includes over a total of 1000 children across Austria, 
Finland, France, Germany and Switzerland.  
An extensive amount of studies in different countries has consistently shown that children 
growing up on a farm or exposed to farm environment develop less atopy and asthma (Braun-
Fahrländer et al. 1999; von Ehrenstein et al. 2000; Riedler et al. 2000; Klintberg et al. 2001). 
Several pathways and cell sub-types are thought to participate in this phenomenon. It was 
shown that blood cells from farming children express significantly increased amounts of 
CD14 and Toll-like receptor 2 in comparison to non-farming children (Lauener et al. 2002), 
suggesting an important role for the innate immune system. 
Furthermore, Treg cells, crucial for the maintenance of immune homeostasis, have also been 
implicated in the “allergy-protective farm effect”. Previously it was demonstrated that 
newborns from farming mothers have a higher number of Treg cells and also that Treg cells 
have an increased suppressive capacity in controllig the responses of effector T cells (Schaub 
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et al. 2009). A different study conducted in Australia with newborns from Papua New 
Guinean mothers, representing a traditional lifestyl  with high microbial burden in 
comparison to neonates from Australian mothers, representing a western lifestyle showed no 
differences between the Treg suppressive capacity within both groups, and increased Treg 
frequency in the Australian neonates (Lisciandro et al. 2012). The differences between the 
studies could be due to different genetic background, different environmental exposures or 
technical differences in cell assessment.  
Farms are known to be microbial heavy-loaded enviroments. In the GABRIELA study, 
bacterial and fungal taxa cultured in the settled mattress dust were more prevalent among 
children living on farms than children in the reference group. In the PARSIFAL study, the 
percentage of samples of mattress dust that were positive for bacteria was higher on 
mattresses from farm children (Ege at al. 2011). 
A recent study in the same cohort has demonstrated that levels of Treg cells are still increased 
during early childhood years (4.5 years) (Lluis, Depn r et al. 2013). In the present study Treg 
cell frequency was not associated with the farm statu  of the child at the age 6 years. However 
despite no observed differences between farming and non-farming children regarding Treg 
cell frequency, the investigation of current farm exposures at the age of 6 years, in particular 
spending time in the stable, was significantly associated with increased levels of Treg cells at 
baseline. Drinking farm milk and contact to hay showed the same direction of increased Treg 
cells at baseline, although effects were not significant. 
In this context it is possible that higher Treg cell numbers, also shown in the aforementioned 
studies with younger children and newborns, might be indicative of an immune regulatory 
mechanism in order to suppress potential high T cell responses to the extremely rich microbial 
burden present in the farm environment. 
In this study, investigation of the suppressive capa ity of Treg cells also revealed no 
significant differences depending on the farming status. Assessing cytokines produced in 
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culture, non-farming children showed a higher decrease in IL-2 when autologous Treg cells 
were in culture in comparison to the farm children. Cytokine competition between different 
cell populations is known to be an important factor determining whether the immune system 
responds or tolerates an antigen (Höfer et al. 2012).  IL-2 secretion and uptake is one of the 
best models of cytokine consumption as a balance mechanism (Höfer et al. 2012). Pandiyan 
and colleagues have used in vitro and in vivo (mouse) models to investigate the apoptosis of 
effector T cells as a consequence to the lack of cyt kines resulting from  consumption by Treg 
cells. It was shown that despite the fact that Treg c lls did not affect the early activation or 
proliferation of effector T CD4+ T cells, they induced effector T cell inhibition by cytokine 
deprivation. IL-2 concentration in culture supernatants with both effector and Treg cells was 
reduced in comparison to single effector T cell culture (Pandiyan et al. 2007).  
In the present study while non-farming children showed a significant decrease of IL-2 in 
culture with Treg cells, farming children showed similar concentrations before and after 
addition of Treg cells. One potential explanation is that non-farming children might tend to 
respond strongly when cells are stimulated. Although not significantly different from the farm 
group, non-farm children had a stronger IL-2 secretion in response to PHA. Thus, Treg cells 
might activate the mechanism of IL-2 consumption in order to stop this exacerbated effector T 
cell response while the response and suppression is not so strong in the farm children group.  
Several components have been suggested to explain the protective farm effect, including the 
microbial diversity (Ege et al. 2011), contact to animals (Remes et al. 2003), endotoxin levels 
(Braun-Farländer et al. 2002) and farm milk consumption  (Riedler et al, 2001; Waser et al. 
2007). Raw farm milk consumption was shown to be associated with a decreased risk for 
asthma and atopy (von Mutius, 2012) and early farm milk drinking (during the first year of 
life) showed an association with lower risk of asthma, atopic sensitization and hay fever 
(Riedler et al.  2001). A study that aimed to determine the key farm milk components that are 
associated with the protective effect has shown that tot l viable bacterial counts and total fat 
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content of the milk was not associated with asthma or topy, however the increased levels of 
whey proteins seemed to be the most relevant components (Loss et al. 2011). In this study it 
was also shown that raw but not boiled milk was associated with asthma, atopy and hay fever.  
In the present study, looking in more detail into specific farm exposures during childhood, 
drinking farm milk during the early years (1 and 1.5 years) showed a significant association 
with higher Treg cell frequency at baseline at the ag  of 6 years. Relation between drinking 
farm milk at such young ages might be reflected at 6 years. However careful interpretation is 
needed as drinking farm milk at that specific age do s not exclude farm milk consumption 
before and after that timepoint. On the other hand, children who were drinking farm milk at 
the ages 4 and 5 years showed mildly lower levels of Treg cells when exposed to Lps in 
culture. Lps is ubiquitous in farm environments. This component is part of the outer wall of 
gram-negative bacteria, thus being a constant exposure to farm children for instance through 
animal contact (Braun-Faerländer et al. 2002).  
A study by Tulic et al. has shown that the timing of the Lps contact (exposure) leads to 
different mechanisms. Exposing sensitized mice with Lps in the first days of sensitization 
abolished the hyperresponsiveness while exposure on later time points exacerbated the 
allergic responses (Tulic et al. 2000). On this note, children who drink farm milk, the majority 
farming children, might be exposed to higher levels of Lps since an early age through 
microbial contact. With continuous immune maturation they might potentially become less 
sensible to Lps exposure thus showing lower levels of Treg cells in vitro.   
Moreover, this modulation through farm milk consumption is in line with the concept that 
farm milk might be one of the most important specific farm exposures for shaping the 
immune system. 
In the present study no associations were found between Treg cell frequency and atopic 
sensitization measured by specific IgE against commn allergens. Even applying a less strict 
cut-off such as Class I ≥ 0.35 IU/ml, no significant results were found. Studies from our lab 
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have shown that neonates from atopic mothers (risk factor) have decreased Treg cell numbers, 
Treg-marker expression and function (Schaub et al. 2008).  At age 4.5 years Treg cell 
frequency was inversely associated with perennial IgE levels (Lluis, Depner at al. 2013). 
Tulic and colleagues have investigated the maturation of thymus-derived Treg cells from birth 
until 14 years and found that overall these cells could suppress proliferative responses of 
effector T cells. However, in nonatopic children Treg cell turnover and suppressive function 
increased with age and paralleled the increase in global thymic FOXP3 mRNA expression. 
This development was delayed in atopic children andthese presented lower levels of Treg 
cells (Tulic et al. 2012). However this was investigated within thymocytes which might not 
directly reflect the levels of Treg cells in peripheral blood and different geographical 
populations (Australian children). 
In our study, investigation of children with current asthma revealed an association with 
increased Treg cells (the lifetime prevalence of asthma showed the same pattern of Treg 
association, yet this was not statistically significant). Qualitatively, the suppressive capacity to 
abolish CD4+CD25- effector T cell division in vitro showed no significant differences 
between non-asthmatics and asthmatics, however the ast matic group produced higher levels 
of IFN-γ at age 6 years. Previously it was shown that low IFN-γ secretion at birth was 
associated with allergen-specific IgE antibodies (Kondo et al. 1998; Pfefferle et al. 2008) and 
thus linked to sensitization. Over all, this emphasize  the importance of the timing, as children 
grow up and  the phenotypes become established it is possible that the immune system tries to 
counteract the biased allergic responses. At age 6 years it is possible that Th1 cells from the 
asthmatic children counter-regulate in vivo in order to control the Th2 exacerbation immune 
response typical in asthmatics, thus adopting an increased IFN-γ production in vitro. While a 
decrease of IFN-γ at birth is associated with increase sensitization (Pfefferle et al. 2008). 
In this study besides IFN-γ modulation in asthmatic children, IL-2 concentrations were also 
affected. As mentioned before, IL-2 consumption is a mechanism used by Treg cells to 
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suppress effector T cell responses (Höfer et al. 2012). The non-asthmatic children showed a 
significant decrease of IL-2 with Treg cells in co-ulture; this was not observed in the 
asthmatic group. Consequently, this regulatory mechanism could be potentially impaired on 
the asthmatic group. 
 
The inverse relation between growing up on farms and sthma development has been shown 
in several epidemiological studies (reviewed in von Mutius, Vercelli, 2010). Additionally, 
several studies have shown the importance of different farm exposures, such as farm milk 
consumption during pregnancy and early years, the number of animal species, contact to hay 
and spending time in stables, on asthma development (reviewed in Mutius, Vercelli, 2010). In 
the PARSIFAL study, Ege and colleagues showed that the asthma-protective effect of being 
raised on a farm could be attributed to pig farming, feeding silage, child’s involvement in 
haying, farm milk and regular stay in animal sheds and barns (Ege t al. 2007). 
The children who were in contact to hay, spending tme inside the stables and also drinking 
farm milk, showed only half of the asthma prevalence rate of non-exposed children. Thus the 
present investigation reinforces the concept of farm exposures and the inverse relation to 
asthma development.  
A few potential limiting aspects of the study need to be considered. For the Treg cell 
functional assays the number a few number of children were included due to cell availability, 
resulting in limited number of children. This did not allow further stratification into subgroups 
(e.g. asthmatic farmer vs asthmatic non-farmer). Confirmation is needed using a larger 
number of subjects. The cytokine concentrations give an overall picture, however it does not 
specify the origin cell, for instance, IL-10 can be both secreted by Th2 and Treg cells. 
Further specific questions have risen and are planned for further analysis such as further 
stratifications in regards to the Treg cell analysis, the influence of boiling the milk, etc. A 
follow-up of this cohort at the age 10.5 years is currently ongoing.  
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The strengths of this study rely on the combination of a comprehensive investigation of 143 
German children from a large international cohort at age 6 years with the assessment of 
regulatory T cells, both quantitatively and qualitatively (frequency and suppressive capacity), 
the investigation of sensitization and asthma including lung function test and an in-depth 
information obtained from detailed questionnaires as essing a wide range of farm exposure 
related questions, disease and clinical outcomes.  
In conclusion, farm exposures in particular farm milk drinking and contact to hay were 
associated with the frequency of regulatory T cells. The specific farm exposures assessed, 
contact to hay, staying in stables and farm milk drinking, were significantly associated with 
lower asthma prevalence. Children with current asthma showed increased Treg cells but no 
significant association with sensitization. The farm or asthma status was not associated with 
Treg suppressive capacity. A modulation of IL-2 and IFN-γ may however play a major role in 
regulatory suppression of effector responses and requires further functional studies. Our 
results reinforce the concept of farm exposures in the protection of asthma.  
This work has shown for the first time the importance of STAT6, TBX21 and HLX1 on 
shaping immune responses, at cytokine and gene expression levels, at birth and disease 
development during early years, in particular with atopic dermatitis and obstructive 
bronchitis. In addition, the present data has shown that farm exposures are inversely 
associated with asthma prevalence and Treg cells are increased in children with current 
asthma. Also, consumption of farm milk during particular childhood time point might be 
reflected on Treg cell levels at age 6 years. Furthermore, IL-2 consumption might be 
regulatory mechanism of suppression differently regulated in non-farming and non-asthmatic 
children.  
Additional investigations in larger cohorts and functional studies are required to support the 
present report and further understand these and other immune mechanism of allergic diseases 
in children. 
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5. SUMMARY   
 
 
Allergic diseases have exponentially increased during the last decades. The complexity of its 
aetiology is due to multifaceted interactions between genetic and environmental factors on the 
development of the immune system. While advances of technology have identified allergy 
susceptibility genes, functional assays are needed to better understand the underlying 
mechanisms. Epidemiological studies have consistently shown that rural/farm environments 
are protective for the development of allergic diseases, including asthma and atopic 
sensitization. Importantly, prenatal and early lifeexposures have been shown to confer the 
strongest protection effects. The mechanisms of howfarming modulates the immune system 
are still not disentangled in detail but include regulation of innate receptors and Regulatory T 
cells. 
In the herewith presented thesis, the following main findings were achieved in the context of 
genetic and immunological influences on development of allergic disease in two different 
birth cohort studies:  
First, 200 neonates were assessed for genetic influence of polymorphisms on neonatal 
immune responses and development of allergic disease  in childhood. The present study 
suggested a role for polymorphisms in the Th2-pathwy, particularly for STAT6 rs324011, on 
immune regulation at an early stage of immune maturation, namely significantly lower Treg-
associated gene expression and Th1-polarization. Polymorphisms in the Th1-pathway, namely 
the transcription factors TBX21 and HLX1, were shown to be relevant in shaping early 
immune responses and mainly Th2 cytokines at birth. Th1 and Th2 genotype-related immune 
responses at birth were partially associated with development of allergic diseases and/or 
protection during early life. These children are currently followed until the age of 6 years to 
further investigate allergic and respiratory disease during age-related immune maturation.  
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Secondly, almost 150 children were investigated at the age of 6 years to assess the role of 
regulatory T cells in relation to farm exposures and clinical outcomes of allergic diseases. Our 
data indicated an inverse association of farm exposures and the prevalence of asthma during 
childhood. Children exposed to hay, stable and farm milk had a lower prevalence of asthma. 
Regarding underlying immune mechanisms, we have detcted that children with contact to 
hay have increased levels of Treg cells and that farm milk intake earlier during childhood can 
still be partially reflected on Treg cells levels at age 6 years. Assessing Treg functional 
mechanisms, changes in cytokine secretion were observed depending on the farming and 
asthmatic status of the children, however confirmation in a larger number of children is 
required 
In summary the present work indicated that Th1 and Th2 polymorphisms were associated 
with modulated immune responses already at birth and influenced allergic disease 
development during the first three years of life. Furthermore, farm exposures were associated 
with a lower prevalence of asthma and associated with modulation of regulatory T cell 
frequency in German children at age 6 years.   
 
 
REFERENCES 
 
80 
 
6. REFERENCES 
 
 Akahoshi M, Obara K, Hirota T, Matsuda A, Hasegawa K, et al. (2005) Functional 
promoter polymorphism in the TBX21 gene associated with aspirin-induced asthma. 
Hum Genet 117: 16-26. 
 Alfven T, Braun-Fahrlander C, Brunekreef B, von Mutius E, Riedler J, et al. (2006) 
Allergic diseases and atopic sensitization in children related to farming and 
anthroposophic lifestyle--the PARSIFAL study. Allergy 61: 414-421. 
 Amoli MM, Hand S, Hajeer AH, Jones KP, Rolf S, et al. (2002) Polymorphism in the 
STAT6 gene encodes risk for nut allergy. Genes Immun 3: 220-224. 
 Arshad SH, Tariq SM, Matthews S, Hakim E (2001) Sensitization to common 
allergens and its association with allergic disorders at age 4 years: a whole population 
birth cohort study. Pediatrics 108: E33. 
 Asher I, Baena-Cagnani C, Boner A, Canonica GW, Chuchalin A, et al. (2004) World 
Allergy Organization guidelines for prevention of allergy and allergic asthma. 83-92 p. 
 Barnes PJ (2008) Immunology of asthma and chronic obstructive pulmonary disease. 
Nat Rev Immunol 8: 183-192. 
 Baru AM, Hartl A, Lahl K, Krishnaswamy JK, Fehrenbach H, et al. (2010) Selective 
depletion of Foxp3+ Treg during sensitization phase ggravates experimental allergic 
airway inflammation. Eur J Immunol 40: 2259-2266. 
 Basagana X, Torrent M, Atkinson W, Puig C, Barnes M, et al. (2002) Domestic 
aeroallergen levels in Barcelona and Menorca (Spain). Pediatr Allergy Immunol 13: 
412-417. 
 Bentley AM, Menz G, Storz C, Robinson DS, Bradley B, et al. (1992) Identification of 
T lymphocytes, macrophages, and activated eosinophils in the bronchial mucosa in 
intrinsic asthma. Relationship to symptoms and bronchial responsiveness. Am Rev 
Respir Dis 146: 500-506. 
 Berger A (2000) Th1 and Th2 responses: what are they? BMJ 321: 424. 
 Bieber T (2008) Atopic dermatitis. N Engl J Med 358: 1483-1494. 
 Bloomfield SF, Stanwell-Smith R, Crevel RW, Pickup J (2006) Too clean, or not too 
clean: the hygiene hypothesis and home hygiene. Clin Exp Allergy 36: 402-425. 
 Braun-Fahrlander C, Gassner M, Grize L, Neu U, Sennhauser FH, et al. (1999) 
Prevalence of hay fever and allergic sensitization in farmer's children and their peers 
living in the same rural community. SCARPOL team. Swiss Study on Childhood 
Allergy and Respiratory Symptoms with Respect to Air Pollution. Clin Exp Allergy 
29: 28-34. 
 Braun-Fahrlander C, Riedler J, Herz U, Eder W, Waser M, et al. (2002) 
Environmental exposure to endotoxin and its relation o asthma in school-age children. 
N Engl J Med 347: 869-877. 
 Casaca VI, Illi S, Suttner K, Schleich I, Ballenberg r N, et al. (2012) TBX21 and 
HLX1 polymorphisms influence cytokine secretion at bir h. PLoS One 7: e31069. 
 Casaca VI, Illi S, Klucker E, Ballenberger N, Schedel M, et al. (2013) STAT6 
polymorphisms are associated with neonatal regulatory T cells and cytokines and 
atopic diseases at 3 years. Allergy 
 Chung HT, Kim LH, Park BL, Lee JH, Park HS, et al. (2003) Association analysis of 
novel TBX21 variants with asthma phenotypes. Hum Mutat 22: 257. 
 Corry DB (2002) Emerging immune targets for the therapy of allergic asthma. Nat 
Rev Drug Discov 1: 55-64. 
 Del Prete G (1992) Human Th1 and Th2 lymphocytes: their role in the 
pathophysiology of atopy. Allergy 47: 450-455 
REFERENCES 
 
81 
 
 Douwes J, Cheng S, Travier N, Cohet C, Niesink A, et al. (2008) Farm exposure in 
utero may protect against asthma, hay fever and eczema. Eur Respir J 32: 603-611. 
 Downs D (2001) Australian experience in general medical practice immunization--
achievements and problems. Vaccine 19: 2413-2417. 
 Duetsch G, Illig T, Loesgen S, Rohde K, Klopp N, et al. (2002) STAT6 as an asthma 
candidate gene: polymorphism-screening, association nd haplotype analysis in a 
Caucasian sib-pair study. Hum Mol Genet 11: 613-621. 
 Ege MJ, Bieli C, Frei R, van Strien RT, Riedler J, et al. (2006) Prenatal farm exposure 
is related to the expression of receptors of the innate immunity and to atopic 
sensitization in school-age children. J Allergy Clin Immunol 117: 817-823. 
 Ege MJ, Frei R, Bieli C, Schram-Bijkerk D, Waser M, et al. (2007) Not all farming 
environments protect against the development of asthma and wheeze in children. J 
Allergy Clin Immunol 119: 1140-1147. 
 Ege MJ, Mayer M, Normand AC, Genuneit J, Cookson WO, et al. (2011) Exposure to 
environmental microorganisms and childhood asthma. N Engl J Med 364: 701-709. 
 Ephrem A, Epstein AL, Stephens GL, Thornton AM, Glass D, Shevach EM. 
Modulation of Treg cells/T effector function by GITR signaling is context-dependent. 
Eur J Immunol. 2013 Sep;43(9):2421-9. 
 Ferris BG (1978) Epidemiology Standardization Project (American Thoracic Society). 
Am Rev Respir Dis 118: 1-120. 
 Frey U, von Mutius E. The challenge of managing wheezing in infants. N Engl J Med. 
2009 May 14;360(20):2130-3. 
 Guerra S, Lohman IC, Halonen M, Martinez FD, Wright AL (2004) Reduced 
interferon gamma production and soluble CD14 levels in early life predict recurrent 
wheezing by 1 year of age. Am J Respir Crit Care Med 169: 70-76. 
 Haley KJ, Sunday ME, Wiggs BR, Kozakewich HP, Reilly JJ, et al. (1998) 
Inflammatory cell distribution within and along asthmatic airways. Am J Respir Crit 
Care Med 158: 565-572. 
 Hancock DB, Romieu I, Chiu GY, Sienra-Monge JJ, Li H, et al. (2012) STAT6 and 
LRP1 polymorphisms are associated with food allergen sensitization in Mexican 
children. J Allergy Clin Immunol 129: 1673-1676. 
 Hartl D, Koller B, Mehlhorn AT, Reinhardt D, Nicolai T, et al. (2007) Quantitative 
and functional impairment of pulmonary CD4+CD25hi regulatory T cells in pediatric 
asthma. J Allergy Clin Immunol 119: 1258-1266. 
 Heinrich J, Richter K, Frye C, Meyer I, Wolke G, et al. (2002) [European Community 
Respiratory Health Survey in Adults (ECRHS)]. Pneumologie 56: 297-303. 
 Herberth G, Heinrich J, Roder S, Figl A, Weiss M, et al. (2010) Reduced IFN-gamma- 
and enhanced IL-4-producing CD4+ cord blood T cells are associated with a higher 
risk for atopic dermatitis during the first 2 yr of life. Pediatr Allergy Immunol 21: 5-
13. 
 Hinz D, Bauer M, Roder S, Olek S, Huehn J, et al. (2012) Cord blood Tregs with 
stable FOXP3 expression are influenced by prenatal environment and associated with 
atopic dermatitis at the age of one year. Allergy 67: 380-389. 
 Hofer T, Krichevsky O, Altan-Bonnet G (2012) Competition for IL-2 between 
Regulatory and Effector T Cells to Chisel Immune Responses. Front Immunol 3: 268. 
 Holloway JW, Yang IA, Holgate ST (2010) Genetics of allergic disease. J Allergy 
Clin Immunol 125: S81-94. 
 Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, et al. Role of LAG-3 
in regulatory T cells. Immunity. 2004 Oct;21(4):503-1 . 
REFERENCES 
 
82 
 
 Jeong CW, Ahn KS, Rho NK, Park YD, Lee DY, et al. (2003) Differential in vivo 
cytokine mRNA expression in lesional skin of intrinsic vs. extrinsic atopic dermatitis 
patients using semiquantitative RT-PCR. Clin Exp Allergy 33: 1717-1724. 
 Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of 
differentiation and function. Annu Rev Immunol. 201;30:531-64. 
 Kemp SF, Lockey RF (2002) Anaphylaxis: a review of causes and mechanisms. J 
Allergy Clin Immunol 110: 341-348. 
 Klinnert MD, Robinson JL (2008) Addressing the psychological needs of families of 
food-allergic children. Curr Allergy Asthma Rep 8: 195-200. 
 Klintberg B, Berglund N, Lilja G, Wickman M, van Hage-Hamsten M (2001) Fewer 
allergic respiratory disorders among farmers' children in a closed birth cohort from 
Sweden. Eur Respir J 17: 1151-1157. 
 Kondo N, Kobayashi Y, Shinoda S, Takenaka R, Teramoto T, et al. (1998) Reduced 
interferon gamma production by antigen-stimulated cord blood mononuclear cells is a 
risk factor of allergic disorders--6-year follow-up study. Clin Exp Allergy 28: 1340-
1344. 
 Lakos G, Melichian D, Wu M, Varga J (2006) Increased bleomycin-induced skin 
fibrosis in mice lacking the Th1-specific transcription factor T-bet. Pathobiology 73: 
224-237. 
 Lauener RP, Birchler T, Adamski J, Braun-Fahrlander C, Bufe A, et al. (2002) 
Expression of CD14 and Toll-like receptor 2 in farme s' and non-farmers' children. 
Lancet 360: 465-466. 
 Lemanske RF, Jr., Busse WW (2010) Asthma: clinical expression and molecular 
mechanisms. J Allergy Clin Immunol 125: S95-102. 
 Lin H, Rathmell JC, Gray GS, Thompson CB, Leiden JM, Alegre ML. Cytotoxic T 
lymphocyte antigen 4 (CTLA4) blockade accelerates th  acute rejection of cardiac 
allografts in CD28-deficient mice: CTLA4 can function independently of CD28. J Exp 
Med. 1998 Jul 6;188(1):199-204. 
 Lisciandro JG, Prescott SL, Nadal-Sims MG, Devitt CJ, Pomat W, et al. (2012) 
Comparison of neonatal T regulatory cell function in Papua New Guinean and 
Australian newborns. Pediatr Allergy Immunol 23: 173-180. 
 Liu J, Radler D, Illi S, Klucker E, Turan E, et al.(2011) TLR2 polymorphisms 
influence neonatal regulatory T cells depending on maternal atopy. Allergy 66: 1020-
1029. 
 Lluis A, Depner M, Gaugler B, Saas P, Casaca VI, et al. (2013) Increased regulatory 
T-cell numbers are associated with farm milk exposure and lower atopic sensitization 
and asthma in childhood. J Allergy Clin Immunol. 
 Lluis A, Schaub B (2012) Lesson from the farm environment. Curr Opin Allergy Clin 
Immunol 12: 158-163. 
 Loss G, Apprich S, Waser M, Kneifel W, Genuneit J, et al. (2011) The protective 
effect of farm milk consumption on childhood asthma and atopy: the GABRIELA 
study. J Allergy Clin Immunol 128: 766-773 e764. 
 Lubin JH, Colt JS, Camann D, Davis S, Cerhan JR, Severson RK, et al. Epidemiologic 
evaluation of measurement data in the presence of dtection limits. Environ Health 
Perspect. 2004 Dec;112(17):1691-6. 
 Maggi E (1998) The TH1/TH2 paradigm in allergy. Immunotechnology 3: 233-244. 
 Masoli M, Fabian D, Holt S, Beasley R (2004) The global burden of asthma: executive 
summary of the GINA Dissemination Committee report. Allergy 59: 469-478. 
 Milkova L, Voelcker V, Forstreuter I, Sack U, Anderegg U, et al. (2010) The NF-
kappaB signalling pathway is involved in the LPS/IL-2-induced upregulation of 
REFERENCES 
 
83 
 
FoxP3 expression in human CD4+CD25high regulatory T cells. Exp Dermatol 19: 29-
37. 
 Monti JM, Vignale R, Monti D (1989) Sleep and nighttime pruritus in children with 
atopic dermatitis. Sleep 12: 309-314. 
 Mullen AC, Hutchins AS, High FA, Lee HW, Sykes KJ, et al. (2002) Hlx is induced 
by and genetically interacts with T-bet to promote heritable T(H)1 gene induction. Nat 
Immunol 3: 652-658. 
 Munthe-Kaas MC, Carlsen KH, Haland G, Devulapalli CS, Gervin K, et al. (2008) T 
cell-specific T-box transcription factor haplotype is associated with allergic asthma in 
children. J Allergy Clin Immunol 121: 51-56. 
 Novak N, Bieber T (2003) Allergic and nonallergic forms of atopic diseases. J Allergy 
Clin Immunol 112: 252-262. 
 O'Connell EJ (2004) The burden of atopy and asthma in children. Allergy 59 Suppl 
78: 7-11. 
 Palomares O, Yaman G, Azkur AK, Akkoc T, Akdis M, et al. (2010) Role of Treg in 
immune regulation of allergic diseases. Eur J Immunol 40: 1232-1240. 
 Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ (2007) CD4+CD25+Foxp3+ 
regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T 
cells. Nat Immunol 8: 1353-1362. 
 Pawankar R, Canonica GW, Holgate ST, and Lockey RF, editors. WAO White Book 
on Allergy. (Milwaukee, Wisconsin: World Allergy Organization), 2011. 
 Perkin MR, Strachan DP (2006) Which aspects of the arming lifestyle explain the 
inverse association with childhood allergy? J Allergy Clin Immunol 117: 1374-1381. 
 Pfefferle PI, Sel S, Ege MJ, Buchele G, Blumer N, et al. (2008) Cord blood allergen-
specific IgE is associated with reduced IFN-gamma production by cord blood cells: 
the Protection against Allergy-Study in Rural Environments (PASTURE) Study. J 
Allergy Clin Immunol 122: 711-716. 
 Remes ST, Iivanainen K, Koskela H, Pekkanen J (2003) Which factors explain the 
lower prevalence of atopy amongst farmers' children? Clin Exp Allergy 33: 427-434. 
 Rengarajan J, Szabo SJ, Glimcher LH (2000) Transcriptional regulation of Th1/Th2 
polarization. Immunol Today 21: 479-483. 
 Riedler J, Braun-Fahrlander C, Eder W, Schreuer M, Waser M, et al. (2001) Exposure 
to farming in early life and development of asthma and allergy: a cross-sectional 
survey. Lancet 358: 1129-1133. 
 Riedler J, Eder W, Oberfeld G, Schreuer M (2000) Austrian children living on a farm 
have less hay fever, asthma and allergic sensitization. Clin Exp Allergy 30: 194-200. 
 Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, et al. (1992) Predominant 
TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 
326: 298-304. 
 Romanet-Manent S, Charpin D, Magnan A, Lanteaume A, Vervloet D (2002) Allergic 
vs nonallergic asthma: what makes the difference? Allergy 57: 607-613. 
 Saetta M, Di Stefano A, Rosina C, Thiene G, Fabbri LM (1991) Quantitative structural 
analysis of peripheral airways and arteries in sudden fatal asthma. Am Rev Respir Dis 
143: 138-143. 
 Sakaguchi S, Miyara M, Costantino CM, Hafler DA (2010) FOXP3+ regulatory T 
cells in the human immune system. Nat Rev Immunol 10: 490-500. 
 Sakaguchi S, Yamaguchi T, Nomura T, Ono M (2008) Regulatory T cells and immune 
tolerance. Cell 133: 775-787. 
 Schaub B, Liu J, Hoppler S, Haug S, Sattler C, et al. (2008) Impairment of T-
regulatory cells in cord blood of atopic mothers. J Allergy Clin Immunol 121: 1491-
1499, 1499 e1491-1413. 
REFERENCES 
 
84 
 
 Schaub B, Liu J, Hoppler S, Schleich I, Huehn J, et al. (2009) Maternal farm exposure 
modulates neonatal immune mechanisms through regulatory T cells. J Allergy Clin 
Immunol 123: 774-782 e775. 
 Schedel M, Carr D, Klopp N, Woitsch B, Illig T, et al. (2004) A signal transducer and 
activator of transcription 6 haplotype influences the regulation of serum IgE levels. J 
Allergy Clin Immunol 114: 1100-1105. 
 Schedel M, Frei R, Bieli C, Cameron L, Adamski J, et al. (2009) An IgE-associated 
polymorphism in STAT6 alters NF-kappaB binding, STAT6 promoter activity, and 
mRNA expression. J Allergy Clin Immunol 124: 583-589, 589 e581-586.  
 Settipane RA, Schwindt C (2013) Chapter 15: Allergic rhinitis. Am J Rhinol Allergy 
27 Suppl 1: S52-55.  
 Shevach EM, Stephens GL. The GITR-GITRL interaction: co-stimulation or 
contrasuppression of regulatory activity? Nat Rev Immunol. 2006 Aug;6(8):613-8. 
 Shevach EM. Immunology. Regulating suppression. Science. 2008 Oct 
10;322(5899):202-3. 
 Shimoda K, van Deursen J, Sangster MY, Sarawar SR, Carson RT, et al. (1996) Lack 
of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 
gene. Nature 380: 630-633. 
 Simons FE (2008) 9. Anaphylaxis. J Allergy Clin Immunol 121: S402-407; quiz S420. 
 Simpson EL. Atopic dermatitis: a review of topical treatment options. Curr Med Res 
Opin. 2010 Mar;26(3):633-40. 
 Skoner DP (2001) Allergic rhinitis: definition, epidemiology, pathophysiology, 
detection, and diagnosis. J Allergy Clin Immunol 108: S2-8. 
 Smith M, Tourigny MR, Noakes P, Thornton CA, Tulic MK, et al. (2008) Children 
with egg allergy have evidence of reduced neonatal CD4(+)CD25(+)CD127(lo/-) 
regulatory T cell function. J Allergy Clin Immunol 121: 1460-1466, 1466 e1461-1467. 
 Strachan DP (1989) Hay fever, hygiene, and household size. BMJ 299: 1259-1260. 
 Suh DC, Sung J, Gause D, Raut M, Huang J, et al. (2007) Economic burden of atopic 
manifestations in patients with atopic dermatitis--analysis of administrative claims. J 
Manag Care Pharm 13: 778-789. 
 Suto A, Nakajima H, Kagami SI, Suzuki K, Saito Y, et al. (2001) Role of CD4(+) 
CD25(+) regulatory T cells in T helper 2 cell-mediated allergic inflammation in the 
airways. Am J Respir Crit Care Med 164: 680-687. 
 Suttner K, Rosenstiel P, Depner M, Schedel M, Pinto LA, et al. (2009) TBX21 gene 
variants increase childhood asthma risk in combinatio  with HLX1 variants. J Allergy 
Clin Immunol 123: 1062-1068, 1068 e1061-1068. 
 Suttner K, Ruoss I, Rosenstiel P, Depner M, Pinto LA, et al. (2009) HLX1 gene 
variants influence the development of childhood asthma. J Allergy Clin Immunol 123: 
82-88 e86. 
 Suzuki K, Kaminuma O, Hiroi T, Kitamura F, Miyatake S, et al. (2008) 
Downregulation of IL-13 gene transcription by T-bet in human T cells. Int Arch 
Allergy Immunol 146 Suppl 1: 33-35. 
 Synek M, Beasley R, Frew AJ, Goulding D, Holloway L, et al. (1996) Cellular 
infiltration of the airways in asthma of varying severity. Am J Respir Crit Care Med 
154: 224-230. 
 Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, et al. (2000) A novel 
transcription factor, T-bet, directs Th1 lineage commitment. Cell 100: 655-669. 
 Takaki H, Ichiyama K, Koga K, Chinen T, Takaesu G, Sugiyama Y, et al. STAT6 
Inhibits TGF-beta1-mediated Foxp3 induction through direct binding to the Foxp3 
promoter, which is reverted by retinoic acid receptor. J Biol Chem. 2008 May 
30;283(22):14955-62. 
REFERENCES 
 
85 
 
 Takeda K, Tanaka T, Shi W, Matsumoto M, Minami M, et al. (1996) Essential role of 
Stat6 in IL-4 signalling. Nature 380: 627-630. 
 Tamari M, Tanaka S, Hirota T (2013) Genome-wide association studies of allergic 
diseases. Allergol Int 62: 21-28. 
 Tulic MK, Andrews D, Crook ML, Charles A, Tourigny MR, et al. (2012) Changes in 
thymic regulatory T-cell maturation from birth to puberty: differences in atopic 
children. J Allergy Clin Immunol 129: 199-206 e191-194. 
 Tulic MK, Wale JL, Holt PG, Sly PD (2000) Modification of the inflammatory 
response to allergen challenge after exposure to bacteri l lipopolysaccharide. Am J 
Respir Cell Mol Biol 22: 604-612. 
 Uzzaman A, Story R (2012) Chapter 5: Allergic rhinitis. Allergy Asthma Proc 33 
Suppl 1: S15-18. 
 Vercelli D (2008) Discovering susceptibility genes for asthma and allergy. Nat Rev 
Immunol 8: 169-182. 
 Vignali DA, Collison LW, Workman CJ (2008) How regulatory T cells work. Nat Rev 
Immunol 8: 523-532. 
 Von Ehrenstein OS, Von Mutius E, Illi S, Baumann L, Bohm O, et al. (2000) Reduced 
risk of hay fever and asthma among children of farmers. Clin Exp Allergy 30: 187-
193. 
 von Mutius E (2000) The burden of childhood asthma. Arch Dis Child 82 Suppl 2: 
II2-5. 
 von Mutius E (2009) Gene-environment interactions in asthma. J Allergy Clin 
Immunol 123: 3-11; quiz 12-13. 
 von Mutius E (2012) Maternal farm exposure/ingestion of unpasteurized cow's milk 
and allergic disease. Curr Opin Gastroenterol 28: 570- 76. 
 von Mutius E, Radon K (2008) Living on a farm: impact on asthma induction and 
clinical course. Immunol Allergy Clin North Am 28: 631-647, ix-x. 
 von Mutius E, Schmid S (2006) The PASTURE project: EU support for the 
improvement of knowledge about risk factors and preventive factors for atopy in 
Europe. Allergy 61: 407-413. 
 von Mutius E, Vercelli D (2010) Farm living: effects on childhood asthma and allergy. 
Nat Rev Immunol 10: 861-868. 
 Waser M, Michels KB, Bieli C, Floistrup H, Pershagen G, et al. (2007) Inverse 
association of farm milk consumption with asthma and llergy in rural and suburban 
populations across Europe. Clin Exp Allergy 37: 661- 70. 
 Weidinger S, Gieger C, Rodriguez E, Baurecht H, Memp l M, et al. (2008) Genome-
wide scan on total serum IgE levels identifies FCER1A as novel susceptibility locus. 
PLoS Genet 4: e1000166. 
 Weidinger S, Klopp N, Wagenpfeil S, Rummler L, Schedel M, et al. (2004) 
Association of a STAT 6 haplotype with elevated serum IgE levels in a population 
based cohort of white adults. J Med Genet 41: 658-663. 
 Weiss ST (2002) Eat dirt--the hygiene hypothesis and allergic diseases. N Engl J Med 
347: 930-931. 
 Williams H, Flohr C (2006) How epidemiology has challenged 3 prevailing concepts 
about atopic dermatitis. J Allergy Clin Immunol 118: 209-213. 
 Zhu J (2010) Transcriptional regulation of Th2 cell differentiation. Immunol Cell Biol 
88: 244-249. 
 
 
 
TABLE INDEX 
 
86 
 
7. TABLE INDEX 
 
 
Table I. Cord blood study: population characteristics. 
 
29 
Table II . Characteristics of the studied polymorphisms. 
 
30 
Table III . Dominant and recessive models comparing results of Treg-related gene 
expression depending on STAT6 rs324011 genotypes.   
 
33 
Table IV. Cytokine secretion in CBMCs in relation to STAT6 rs1059513 and 
rs324011 polymorphisms.  
 
35 
Table V. Dominant and recessive models comparing results of cyt kine secretion 
depending on STAT6 polymorphism.   
 
37 
Table VI. Correlations of FOXP3 expression with cytokine secretion in CBMCs 
depending on STAT6 polymorphisms.  
 
40 
Table VII . Effects of TBX21 and HLX1 polymorphisms on cytokine secretion, T 
cells and mRNA regulation.  
 
46 
Table VIII . Prevalence of clinical outcomes in children in relation to STAT6 
rs324011 genotypes.  
47 
 
 
 
 
 
 
TABLE INDEX 
 
87 
 
Table IX. Distribution of minor allele frequencies of the STAT6 polymorphisms in 
neonates from atopic and nonatopic mothers. 
 
48 
Table X. Distribution of minor allele frequencies of the TBX21 and HLX1 
polymorphisms in neonates from atopic and non-atopic mothers.  
 
49 
Table XI. PASTURE/EFRAIM 6 year old population characteristic at age of 6 
years. 
 
52 
Table XII . Association of farm and current farm exposures with Treg cell 
frequency at age of 6 years. 
  
54 
Table XIII . Effector T cell division and Treg Suppressive Capacity in 6 year old 
EFRAIM children. 
 
58 
Table XIV. Cytokine concentrations with and without Treg cells. 
 
59 
Table XV. Treg cells in sensitized and non-sensitized 6 year old children. 
 
61 
Table XVI . Farm exposures during childhood and association with the prevalence 
of asthma. 
63 
 
 
 
 
FIGURE INDEX 
 
88 
 
8. FIGURE INDEX 
 
Figure 1. T cells are characterized by their transcription factors as well as different 
cytokine secretion patterns.  
 
9 
Figure 2. STAT6 rs324011 allele is associated with downregulation of Treg-cell related 
markers.  A) FOXP3; B) GITR; C) LAG3. Corresponding box plots represent mRNA 
expression in ∆Ct (normalized with 18S); higher ∆ct represents lower mRNA expression 
and vice-versa. Data were shown as medians, first and third quartile. WT = wildtype, HT = 
heterozygous, SNP = SNP homozygous, U = Unstimulated, LpA = Lipid A, Ppg = 
Peptidoglycan, Derp1 = Dermatophagoides pteronyssinus. Data were analyzed with 
Kruskal-Wallis test. Maximum number for gene expression analysis: STAT6 rs324011 n 
(WT) = 43; n (HT) = 55; n (SNP) = 10. (Casaca et al. 2013). 
 
32 
Figure 3. Cytokine secretion of wildtype, heterozygous and homozygous SNP carriers of 
TBX21 rs17250932 and HLX1 rs2738751. Data were shown in boxplots (first, third quartile, 
median), the whiskers indicate the maximum and minium values, dots indicate outliers, 
analyzed by Kruskal-Wallis-test. Values were shown in pg/ml.  n (WT) = 113, n (HT) = 61, 
n (SNP) = 10, and HLX1 rs2738751 n (WT) = 135, n (HT) = 45, n (SNP) = 4. 
 
43 
Figure 4. Cytokine secretion of wildtype, heterozygous and homozygous SNP carriers of 
HLX1 rs12141189. Data were shown in boxplots (first, third quartile, median), the whiskers 
indicate the maximum and minimum values, dots indicate outliers, analyzed by Kruskal-
Wallis-test. Values were shown in pg/ml. n (WT) = 104, n (HT) = 68, n (SNP) = 12. 
 
 
44 
Figure 5. Representative flow cytometry plots of Treg cell makers after PI-stimulation. 
Treg cells were identified by CD4, high levels of CD25 (upper top 20 % cells) and FOXP3.  
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Figure 6. Association of Treg cell percentages at age 6 withfarm milk consumption from 
pregnancy until age of 6 years at Media (baseline) and upon Lps. Preg: Media: FM=60 
NFM=67. 1y:FM=45 NFM=82. 1.5y: FM=52 NFM=73. 2y: FM=60 NFM=67. 3y: FM=59 
NFM=67. 4y:FM=59 NFM=68. 5y: FM= 62 NFM=63. 6y: FM=55 NFM=72. Lps: Preg: 
FM=64 NFM=69. 1y:FM=47 NFM=86. 1.5y: FM=53 NFM=78. 2y: FM=60 NFM=73. 3y: 
FM=61 NFM=71. 4y:FM=62 NFM=70. 5y: FM=67 NFM=64. 6y: FM=60 NFM=73. * p ≤ 
0.05. # p ≤ 0.01. 
 
56 
Figure 7. Treg suppression, measured by decrease of CFSE staining during division 
effector T cells. Left plot shows division of PHA-stimulated effector T cells without 
addition of Treg cells. Middle and right plots show the abolishment of effector T cell 
division (P4) with addition of Treg cells in differnt ratios (1:0.5 and 1:0.25, respectively). 
 
57 
Figure 8. Concentration of IL-2 (pg/ml). NF = Non farming children; F = Farming 
children.  NF = 10; F = 7.  
 
60 
Figure 9. IL-2 and IFN-γ concentrations (pg/ml) in asthmatics and non-asthma ics at the 
age of 6 years. A) IFN-γ secretion in response to PHA-stimulation, Antigen presenting 
cells, CD3+ and effector T cells, CD4+CD25- in culture. B) IFN-γ secretion in response to 
PHA-stimulation, Antigen presenting cells, CD3+, effector T cells, CD4+CD25- and Treg 
cells CD4+CD25+ in culture. Linear mixed model. 
62 
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9. ABBREVIATIONS 
 
Abs = Antibodies 
AD = Atopic dermatitis 
CBMCs = Cord blood mononuclear cells 
CI = Confidence interval 
CT = Cycle threshold 
Derp1 = Dermatophagoides pteronyssinus 
FOXP3 = Forkhead-Box-Protein P3 
GATA3 = GATA-binding protein 3 
GITR = Glucocorticoid-induced tumor necrosis factor receptor 
GM-CSF = Granulocyte macrophage colony-stimulating factor 
GMR = Geometric mean ratio 
HT = Heterozygotes 
HWE = Hardy-Weinberg equilibrium 
IFN-γ = Interferon gamma 
LAG3 = Lymphocyte-activation-gene 3 
LpA = Lipid A 
LPS = Lipopolysaccharide 
MAF = Minor allele frequency 
NF-κB= Nuclear factor 'kappa-light-chain-enhancer' of activated B-cells 
OR = Odds Ratio 
PBMC = Peripheral blood mononuclear cells 
PI = PMA/Ionomycin; 
PMA = Phorbol 12-myristate 13-acetate 
Ppg = Peptidoglycan 
RAST = Radioallergosorbent test 
SD = Standard deviation;  
SNP = Single nucleotide polymorphism 
STAT6 = Signal transducer and activator of transcription 6 
TCR = T-cell receptor 
TGF-β1 = Transforming growth factor beta1 
Treg cells = Regulatory T cells 
U = Unstimulated 
WT = Major allele homozygotes 
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